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The limited number of oral vaccines currently approved for use in humans and veterinary species clearly
illustrates that development of efﬁcacious and safe oral vaccines has been a challenge not only for ﬁsh
immunologists. The insufﬁcient efﬁcacy of oral vaccines is partly due to antigen breakdown in the harsh
gastric environment, but also to the high tolerogenic gut environment and to inadequate vaccine design.
In this review we discuss current approaches used to develop oral vaccines for mass vaccination of
farmed ﬁsh species. Furthermore, using various examples from the human and veterinary vaccine
development, we propose additional approaches to ﬁsh vaccine design also considering recent advances
in ﬁsh mucosal immunology and novel molecular tools. Finally, we discuss the pros and cons of using the
zebraﬁsh as a pre-screening animal model to potentially speed up vaccine design and testing for
aquaculture ﬁsh species.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Aquaculture has been the fastest growing food-producing sector
for years and the yield of aquaculture has overgrown the yield of
wild capture ﬁsheries (FAO, 2014). As a downside of this sector-
wide intensiﬁcation, increasing stocking densities give rise to
high stress levels which in turn make ﬁsh more vulnerable to in-
fections. Prevention of disease outbreaks is therefore essential to
prevent serious economic losses and thus the development or
reﬁnement of targeted vaccines for aquaculture species is
imperative.
To date vaccines are available for most aquaculture ﬁsh species;
most are targeting bacterial pathogens and only a few are raised
against viruses. Depending on the age and size of the ﬁsh, com-
mercial vaccines are administered either orally (by mixing with the
feed), by immersion (dip or bath) or by injection through the
intraperitoneal (i.p.) or intramuscular (i.m.) route. Intraperitoneal
injection is conventionally used to deliver water-in-oil (w/o)-based
injectable vaccines whereas intramuscular injection is most often
used to deliver DNA plasmids (reviewed in Brudeseth et al. (2013)).
While protection is generally highest with injection-vaccination, it
is also associated with intensive handling and stress for the ﬁsh.-like receptor; RLR, RIG-like
a).
r Ltd. This is an open access articleFurthermore, depending on the type of adjuvant used, w/o-based
injectable vaccines have been associated with local side effects
including tissue inﬂammation, adhesion and necrosis. Fish that are
too small to be injected are usually vaccinated orally or by im-
mersion, but these routes usually result in low efﬁcacy and short
protection. To ensure protection throughout the entire production
cycle, vaccination regimes have been developed for various species
in which a combination of immersion, oral and injection vaccina-
tion is used. In most cases, it is only after injection with w/o-based
vaccines that strong and long lasting protection is achieved.
There is no doubt that with respect to animal welfare and
handling costs, the mucosal route of vaccination, and in particular
the oral route, would be the ideal method of vaccine delivery.
Nevertheless, owing to the high costs of vaccine production
required for immersion vaccination or the limited efﬁcacy of the
current oral formulations, mass vaccination of ﬁsh, exclusively via
the mucosal routes, is not common practice.
While nowadays improvement of current oral vaccination
strategies is a major topic in ﬁsh vaccine development, the ﬁrst
report on a successful oral vaccine was already reported in 1942.
The study showed protection of trout against a challenge with
Bacterium salmonicida after prolonged feeding (64e70 consecutive
days) with chloroform-inactivated bacteria (Duff, 1942). In the 80s
and 90s considerable attention was drawn to the development of
oral vaccines for ﬁsh. During this period, morphological and func-
tional differences within the intestine were investigated and the
second segment was identiﬁed as the main place of antigen uptakeunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1985; Noaillac-Depeyre and Gas, 1973; Rombout and van den Berg,
1989; Rombout et al., 1989; Stroband and Kroon, 1981). This
knowledge highlighted the necessity of protecting antigens from
being broken down in the stomach and foregut of the ﬁsh. The need
for antigen protection was conﬁrmed by comparing the uptake of
antigens, induced immune responses and vaccine efﬁcacy after oral
or anal administration. Higher vaccine efﬁcacy of anal vaccination
in comparison to oral vaccination using the same vaccine was re-
ported for many studies including vaccination against Vibrio
anguillarum (V. anguillarum) and Yersinia ruckeri (Y. ruckeri) for
salmon (Johnson and Amend, 1983) or against V. anguillarum in
carp (Rombout et al., 1986).
The overall limited efﬁcacy of oral vaccines in ﬁsh, as in other
veterinary species or in humans, is not only due to problems linked
to antigen breakdown in the harsh gastric environment, but also to
the highly tolerogenic gut environment. The phenomenon of (oral)
tolerance is well known in ﬁsh as well (Joosten et al., 1997; Maurice
et al., 2004; Rombout and Kiron, 2014; Rombout et al., 1989), but
the mechanisms associated to its development have not been sys-
tematically addressed. The potential risk of tolerance induction
upon oral vaccination, especially in immunologically immature
young ﬁsh, is therefore an additional factor that ﬁsh immunologists
have to take into account while developing mucosal vaccines.
From studies in mammals it is well established that mucosal
tolerance is dependent on antigen dose and route of administration
(Faria and Weiner, 2005). Mucosal tolerance is driven by the
expression of high local levels of anti-inﬂammatory cytokines (IL-
10 and TGFb) that sustain the generation and maintenance of tol-
erogenic regulatory T cells and dendritic cells (DCs) (Weiner and
Wu, 2011). Therefore potent mucosal adjuvants as well as tar-
geted delivery strategies are being used for oral vaccine develop-
ment in humans and veterinary species. For example, the use of live
attenuated vaccines targeting mucosal dendritic cells or microfold
epithelial cells (M cells), administered along with strong adjuvants
(i.e. bacterial toxins) has received signiﬁcant attention and holds
great promise to facilitate the induction of effective mucosal re-
sponses (Fujkuyama et al., 2012; Neutra and Kozlowski, 2006).
This reviewwill summarize current knowledge on experimental
oral vaccines in human and veterinary species, with a particular
focus on ﬁsh, focusing on antigen type, dose, encapsulation as well
as delivery methods. First, based on all summarized work we will
try to extrapolate communalities among all (successful) approaches
with a special focus on the nature of the pathogen, nature of the ﬁsh
and vaccination strategy. Next, using several examples from the
human and veterinary ﬁeld, we will dissect the conditions that
might lead to tolerance to orally delivered antigens in ﬁsh and later,
the protective immune mechanisms that need to be rationally
targeted to overcome tolerance and achieve successful oral vacci-
nation. Among others, we will discuss the possibility to target local
antigen presenting cells (APCs) or M-like antigen-sampling cells
(Fuglem et al., 2010) as well as the choice of mucosal adjuvants that
can either promote antigen adhesion to M-like cells, or strongly
activate local innate and adaptive immune responses. Finally, we
will discuss the pros and cons of using zebraﬁsh as a pre-screening
platform for novel oral vaccination approaches for cultured ﬁsh
species.
2. Is development of ﬁsh oral vaccines really lagging behind?
Current status on human and veterinary oral vaccines
In mammals it is well known that parenteral antigen adminis-
tration triggers weak mucosal responses, whereas antigen admin-
istration at mucosal surfaces efﬁciently triggers local as well as
systemic humoral and cell-mediated responses (Neutra andKozlowski, 2006). The importance of triggering speciﬁc immune
responses at mucosal surfaces for protection against mucosal
pathogens is well recognized. Despite this, in humans, as in many
veterinary species, the development of effective oral vaccines has
gone at a slow paste. In fact, after more than 100 years of research,
only ﬁve mucosal vaccines have been approved for human use.
These include four oral vaccines against polio virus, rotavirus, Sal-
monella typhi (S. thypi), and Vibrio cholera (V. cholera) and one nasal
vaccine against inﬂuenza virus (B€ohles et al., 2014; Lamichhane
et al., 2014; Neutra and Kozlowski, 2006). Perhaps not surprising,
but also these vaccines do not trigger a long-lasting protection and
they all require boosting after 2 years from ﬁrst administration in
adults, and 6 months in children aged 2e5 years. Many oral vac-
cines for human application are currently in various developmental
phases and clinical testing, but often safety issues or adverse side
effects slow their implementation. Altogether this underlines how,
also in humans, optimal conditions to achieve effective oral vacci-
nation have not been deﬁned yet and how challenging the ﬁeld of
mucosal vaccine development can be.
The situation for veterinary oral vaccines (for non-ﬁsh species)
is perhaps a little better, with a very successful oral vaccine against
rabies virus, which helped eradicate rabies disease from wildlife
reservoirs in Europe and most of the United States, and one oral
vaccine for pigs against the intracellular bacterium Lawsonia
intracellularis (Meeusen et al., 2007). Several mucosal (oral) vac-
cines are available from various vaccine companies for pigs and
cows against rotavirus and for poultry against several pathogens:
turkey adenovirus; infectious bronchitis virus; Newcastle virus;
infectious bursitis virus; chicken herpesvirus; turkey herpesvirus;
reovirus; Bordetella avium; Pasteurella multocida (Gerdts et al.,
2006).
Considering the total number of commercially available vaccines
against ﬁsh pathogens, only a small but signiﬁcant proportion is
administered orally (reviewed in (Brudeseth et al. (2013); Dhar
et al. (2014); Sommerset et al. (2014)). For salmonid species, com-
mercial oral vaccines are available for Atlantic salmon and coho
salmon against Piscirickettsia salmonis (P. salmonis), infectious
pancreatic virus (IPNV), and infectious salmon anaemia virus
(ISAV); for rainbow trout against IPNV, Y. ruckeri, P. salmonis and for
rainbow trout and sea bass against V. anguillarum. For Great
amberjack one oral vaccine has been licensed in Japan against
Lactococcus garviae (L. garviae). Despite their commercialisation
however, oral vaccines for ﬁsh are in use in a few countries only
(mainly Chile, Norway and Scotland) (Brudeseth et al., 2013).
Similar to the human oral vaccines, oral vaccines for ﬁsh provide
only a weak or short protection and are therefore mostly used as
prime and/or booster vaccination. Depending on the ﬁsh species
and production cycle, farmers will optimally choose for a vaccina-
tion regime starting with dip vaccination, followed by booster
vaccination (dip or oral) and ﬁnally an injection vaccination
(Brudeseth et al., 2013). Such vaccination regime generally confers
strong and long-lasting protection during the entire production
cycle. However, it causes more stress to the ﬁsh and is more costly
and labour intensive for the farmer. Therefore considerable effort is
still dedicated to the improvement of currently available vaccines
and to design new oral vaccination strategies that can provide
stronger and longer lasting protection in ﬁsh.
3. Successes and concerns of current mucosal human and
veterinary vaccines
When considering the nature of the pathogen, all oral vaccines
licensed for use in humans and veterinary species are against
mucosal pathogens that either infect the mucosal surface itself or
use the mucosa as portal of entry to then establish a systemic
C.W.E. Embregts, M. Forlenza / Developmental and Comparative Immunology 64 (2016) 118e137120infection. Furthermore, with only few exceptions, successful oral
vaccines are based on live attenuated viruses or bacteria that
closely mimic the route of infection of the pathogen and trigger
strong local immune responses without the need for any additional
adjuvant. For example, the live attenuated poliovirus and S. typhi
vaccines are derived from pathogens that preferentially adhere to
M cells and exploit M-cell transport to invade organized mucosal
lymphoid tissues in the intestine (Jones et al., 1994; Sicinski et al.,
1990).
As a downside, live attenuated vaccines are less safe as it cannot
be guaranteed that the pathogen would not revert to the virulent
form or cause pathogenesis in few individuals. This has been
already observed for the oral polio vaccine in humans for which 1 in
a million doses caused a so-called ‘vaccine-associated paralytic
polio’ (WHO, 2014). This reﬂects the importance and risks associ-
ated to the use of live attenuated vaccines and the need for
development of even safer and rationally designed vaccines.
The challenges however are not only in the development of safer
vaccines for humans, but also for veterinary species including
poultry. It is now been ascertained that imperfect vaccination
against Marek's disease virus (MDV) can drive the generation and
enhance the transmission of highly virulent pathogens (Read et al.,
2015). Spray-vaccination of chickens with live attenuated MDV
gives rise to the considerable risk that not all chickens are exposed
to the same dose of the vaccine, if at all. The vaccine effectively
protects vaccinated individuals but fails to induce sterile immunity,
as vaccinated chickens are still able to shed the vaccine virus. In this
situation, in order to be able to survive in a population of largely
vaccinated animals, the virus is driven towards increased virulence.
This example clearly highlights how not only the design but also
the administration route of a successful vaccine plays a crucial role
in tilting the balance between immunity and pathogenesis.
When considering the currently licensed oral vaccines for ﬁsh
we realise that all are based on heat- or formalin-killed pathogens.
Most of these pathogens are however either enteric pathogens,
such as Y. ruckeri and V. anguillarum, or enter and affect mucosal
organs, such as P. salmonis or IPNV. Furthermore, although no
speciﬁc adjuvants arementioned to be administered along with the
vaccine antigen, most vaccines are either incorporated in an Anti-
gen Protecting Vehicle (Y. ruckeri, V. anguillarum and IPNV vaccines,
MSD-Animal Health) or in patented MicroMatrix™ delivery system
(P. salmonis, ISAV and IPNV, Centrovet). Such encapsulations or
delivery methods are aimed at protecting the antigens from gastric
degradation, but might also promote antigen uptake by enhancing
adhesion to mucosal surfaces. Moreover, they might possibly act as
adjuvants by providing local inﬂammatory signals (Plant and
Lapatra, 2011). The use of inactivated pathogens certainly poses
an advantage with respect to (environmental) safety but, together
with the lack of strong mucosal adjuvants, it might still be one of
the causes of the weak and short protection provided by these
vaccines.
Interestingly, prolonged protection against P. salmonis and ISA
virus can be achieved in farmed salmonids, but only upon admin-
istration of MicroMatrix™-encapsulated oral vaccines at repeated
intervals of approximately 1200 degree-days (approximately 3
month for salmon kept at 11e12) (Tobar et al., 2015). Protection
was found to correlate to high serum IgM levels whereas the
window of disease susceptibility was shown to coincide with the
decline in IgM serum levels. Therefore, repeated oral administra-
tions assured that serum IgM remained high throughout the entire
production cycle and this conﬁrmed once again that oral antigen
administration can elicit systemic responses (Rombout et al., 1989).
Furthermore, while it is clear that on the one hand ﬁsh do not
develop a strongmemory response to the vaccine, they on the other
hand also do not develop tolerance. The possible mechanismsbehind such phenomenon are not fully understood. It is possible
that the vaccine dose combined with the MicroMatrix™ provides
sufﬁcient signals (inﬂammatory and co-stimulatory) to activate B
cells directly and drive them towards few rounds of division and
antibody production. Nevertheless, as it will be further discussed in
section 6.2, the lack of immune memory and tolerance upon anti-
gen re-exposure might be explained by the failure of the vaccine to
activate cell-mediated T cell responses required for effective B cell
activation and memory formation. Given the promising but insuf-
ﬁcient progress on ﬁsh oral vaccine development, substantial
research effort is still being dedicated to the study of mucosal im-
mune responses in ﬁsh and the generation of novel oral vaccines.
4. Current strategies and efﬁcacy of experimental non-
encapsulated oral ﬁsh vaccines
Given the relative success of the currently licensed ﬁsh vaccines,
as well as the convenience and safety of inactivated pathogens, a
large number of studies focused on the use of non-encapsulated
(inactivated) bacteria, yeast or plants expressing bacterial or viral
antigens. This approach is largely based on the hypothesis that
antigens expressed in whole cells might not need further encap-
sulation since the cell wall itself might act as natural protection
barrier against the intestinal environment. A selected overview of
the current experimental approaches for the development of oral
vaccines against bacterial and viral pathogens using non-
encapsulated antigens is presented in Table 1 and will be dis-
cussed in this section. A more extensive and detailed summary is
presented in Supplementary Table 1. Although many reports could
be found describing vaccine uptake and local responses, we selec-
tively focused on those studies that also tested vaccine efﬁcacy upon
pathogen challenge (see references in (supplementary) Table 1).
Independently of the dose, regime, nature of the pathogen or
vaccine type, it is apparent that when protection could be observed,
this was either assessed after only a very short time following last
vaccine administration or was found to decrease within 2e3
months after vaccination. In most cases single or consecutive ad-
ministrations, or consecutive administration with varying time
intervals, did not make a signiﬁcant difference in survival. This
suggests that the dose achieved by a single administration or by
consecutive administration is sufﬁcient to induce a response and
confer protection, at least within the time tested.
Interestingly, two studies showed that the addition of common
injectable adjuvants (alum and Freund's incomplete) to the oral
vaccine had a positive effect on vaccine efﬁcacy. Addition of 25% v/v
of 10% potassium aluminium sulphate (alum) increased survival of
rainbow trout against V. anguillarum using different types of whole
cell vaccines, when compared to the same vaccines without adju-
vant (Agius et al., 1983), Supplementary Table 1. The addition of
incomplete Freund's adjuvant (20% v/v) to a formalin-killed Strep-
tococcus agalactiae (S. agalactiae) vaccine increased survival of red
tilapia upon i.p. challenge with S. agalactiae,when compared to the
non-adjuvanted vaccine (Firdaus-Nawi et al., 2013), Table 1.
Nevertheless, long-term protection and potential side effects were
not investigated.
Of interest, few approaches showed the potential of using
enteric pathogens not affecting ﬁsh or commensal microbes as
vaccine vehicles (Table 1). Formalin-inactivated Escherichia coli
(E. coli) expressing S. agalactiae or grass carp reovirus (GCRV) an-
tigens, and live attenuated Salmonella typhimurium
(S. typhimurium) expressing surface immunogenic protein (Sip) of
S. agalactiae generally conferred good protection at various vacci-
nation doses. Similarly, live Lactococcus lactis expressing Aeromonas
hydrophila antigens, Lactobacillus plantarum (L. plantarum)
expressing Spring Viremia of Carp Virus (SVCV) or Cypinid
Table 1
Experimental approaches for the development of oral vaccines using non-encapsulated antigens.
Pathogen Fish species Regime and
formulation
Antigen Dose Protection
(survival)
Time of
challenge
Challenge
route
Reference
Bacteria
Aeromonas
hydrophila (A.h.)
Catla (3.8 g), rohu
(3.4 g), common
carp (4 g)
15d; Mixed with
feed
h.i. A.h. bioﬁlm
grown on chitin
ﬂakes
107 CFU/ﬁsh/day 0e25% RPS 20 dpv i.m. (Azad et al., 1999)
25e35% RPS 40 dpv
30e60% RPS 60 dpv
1010 or 1013
CFU/ﬁsh/day
20e45% RPS 20 dpv
35e50% RPS 40 dpv
75e80% RPS 60 dpv
10d, 15d or 20d;
Mixed with feed
h.i. A.h. bioﬁlm on
chitin ﬂakes
1010 CFU/ﬁsh/day;
for 10d
15e55% RPS 20 dpv
45e44% RPS 40 dpv
35e75% RPS 60 dpv
25e40% RPS 150 dpv
1010 CFU/ﬁsh/day;
for 15d
35e60% RPS 20 dpv
65e80% RPS 40 dpv
45e100% RPS 60 dpv
35e60% RPS 150 dpv
1010 CFU/ﬁsh/day;
for 20d
20e55% RPS 20 dpv
75e90% RPS 40 dpv
35e100% RPS 60 dpv
30e55% RPS 150 dpv
Aeromonas
hydrophila
Gibel carp (50 g) 2 times 5d,
14d interval;
Mixed with feed
F.i. whole cells or
cell ghosts
4  108 cell
ghosts/g ﬁsh/day
78% 30 dpv i.p. (Tu et al., 2010)
4  108 cells/g
ﬁsh/day
61%
Control 5%
Aeromonas
hydrophila
Tilapia (17e18 g) 4 weeks;
Mixed with feed
L. lactis expressing
aerolysin genes D1
and D4 from A.h.
106 CFU/g of feed D1: 85% 1 dpv i.p. (Anuradha et al.,
2010)D4: 70
108 CFU/g of feed D1: 100%
D4: 85%
Controls 25e40%
Edwardsiella
tarda (E.t.)
Olive ﬂounder
(4e5 g)
One time only, or
with boost at 14d;
Gavage
Autotrophic
mutant DalrDasd
E. tarda
108 CFU/ﬁsh 90e100% 3 wpv i.p.,
Bath
(Choi et al., 2011)
109 CFU/ﬁsh 100%
108 CFU/ﬁsh,
108 CFU/ﬁsh for
boost
60e65%
109 CFU/ﬁsh,
108 CFU/ﬁsh for
boost
100%
Controls 0e18%
Edwardsiella
tarda
Olive ﬂounder
(4e5 g)
One time only, or
with boost at 14d;
Gavage
Autotrophic
mutant DalrDasd
E. tarda
108 CFU ﬁsh 90e100% 3 wpv i.p.,
Bath
(Choi et al., 2011)
109 CFU/ﬁsh 100%
108 CFU/ﬁsh,
108 CFU for boost
60e65%
109 CFU/ﬁsh,
108 CFU for boost
100%
Controls 0e18%
Edwardsiella
ictaluri (E.i.)
Channel catﬁsh
(7e9 cm)
One time;
Mixed with feed
Live attenuated
E. ictaluri
4.6e6 x 106 CFU/g
feed
92e100% 29 dpv Bath, cohab (Wise et al., 2015)
4.6e6 x 107 CFU/g
feed
97e100%
Field trial;
1.9  106 CFU/g
feed
V: 54%
C: 28%
Photobacterium
damsela (P.d.)
Sea bass (20 g) One time;
Gavage
F.i. whole P.d. and
extracellular
components
500 ml V: 64% 6 wpv Bath (Bakopoulos et al.,
2003)C: 31%
V: 55% 12 wpv
C: 19%
Flavobacterium
psychrophilum
(F.p.)
Ayu (0.5 g) 3d or 15d with 5d
interval; repeated 5
or 15 times;
Mixed with feed
F.i. F. psychrophilum 0.1e0.2 g
bacteria/kg;
5 times: 53e94% 3 wpv Bath (Kondo et al., 2003)
15 times: 92e97%
C: 35e69%
5 times: 76e87% 7 wpv
15 times: 79e88%
C: 42e76%
Flavobacterium
psychrophilum
Rainbow trout
(1.6 g)
10 times on
alternating days;
Mixed with feed
Membrane vesicles
(supernatatant)
and f.i. F.p. of
stationary (SP) and
logarithmic phase
(LP)
1250 ml
supernatant (SN)
and 0.2 g cells/kg of
ﬁsh
SP cells: 66e68% 3 wpv Bath (Aoki et al., 2007)
LP cells: 94%
SP þ SN: 47e53%
LP þ SN: 51%
LP þ SN þ SP: 59%
SP þ SN þ SP: 97
e100%
C: 56.3e44.1%
Streptococcus
agalactiae (S.a.)
Nile tilapia (100 g) 1,2 or 3 times with
1 week interval
Gavage
Live attenuated
S. typhimurium
expressing surface
1  107 CFU/ﬁsh;
1e3 times
1: 20% RPS 7 dpv i.p. (Huang et al., 2014)
2: 30% RPS
3: 47% RPS
(continued on next page)
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Table 1 (continued )
Pathogen Fish species Regime and
formulation
Antigen Dose Protection
(survival)
Time of
challenge
Challenge
route
Reference
immunogenic
protein of S.a.
1  108 CFU/ﬁsh; 1
e3 times
1: 27% RPS
2: 40% RPS
3: 53% RPS
1  109 CFU/ﬁsh; 1
e3 times
1: 33% RPS
2: 47% RPS
3: 57% RPS
Controls 0%
Streptococcus
agalactiae
Nile tilapia (30 g) 1, 2 (6d interval) or
3 times (3d
interval);
Mixed with feed
Live attenuated
S. agalactiae
107 CFU/ﬁsh; 1e3
times
1: 50% 15 and
30 dpv
i.p. (Li et al., 2015)
2: 64%
3: 67%
108 CFU/ﬁsh; 1e3
times
1: 69%
2: 81%
3: 79%
109 CFU/ﬁsh; 1e3
times
1: 72%
2: 85%
3: 72%
Control 33%
Streptococcus
agalactiae
Red hybrid tilapia
(100 g)
2 times with 14d
interval;
Mixed with feed
F.i. E. coli
expressing S.a. cell
wall surface anchor
family protein
1  106 CFU/g of
feed
V: 70% 4 wpv Bath (Nur-Nazifah et al.,
2014)C: 0%
Streptococcus
agalactiae
Red tilapia (100 g) 2 times with 14d
interval;
Mixed with feed
F.i. S. agalactiae 6.7  107 CFU/ml 50% 14 dpv i.p. (Firdaus-Nawi
et al., 2013)6.7  107 CFU/ml
with 1:6 v/v FIA
100%
Control 12%
Streptococcus iniae
(S.i.)
Nile tilapia (12.7 g) 1d or 5d;
Mixed with feed
Oralject technique-
1
(O-1);
Oralject technique-
2
(O-2);
lyophilized S. iniae
O-1, 2  109
bacteria/ﬁsh/day;
1d
82% 23 dpv i.p. (Shoemaker et al.,
2006)
O-2, 2  109
bacteria/ﬁsh/day;
1d
77%
O-1, 2  108
bacteria/ﬁsh/day;
5d
78%
O-2, 2  108
bacteria/ﬁsh/day;
5d
68%
Control 53%
Vibrio anguillarum
(V.a.)
Atlantic halibut
(40 g)
One time;
Gavage
Fy-i. V.a. 100 ml bacteria/ﬁsh V: 50% 12 wpv i.p. (Bowden et al.,
2002)C: 0%
Yersinia ruckeri
(Y.r.)
Rainbow trout
(13.4 g)
One time or
boosted after 4 m;
Mixed with feed
F.i. Y. ruckeri or
AquaVac ERM Oral
(AV)
108 CFU/ﬁsh Y.r: 72% 2 m after
booster
Bath (Villumsen et al.,
2014)AV: 48%
108 CFU/ﬁsh plus
5 107 CFU booster
Y.r: 72%
AV: 80%
5  109 CFU plus
booster
Y.r: 100%
Control 44%
Viruses
Viral heamorrhagic
septicemia virus
(VHSV)
Rainbow trout (40
e80 g)
3d;
Mixed with feed
Attenuated
lyophilized VHSV,
PEG pellets
4.8e5.7 TCID50/ﬁsh
total
V: 77e91% 6 wpv bath (Adelmann et al.,
2008)C: 30e41%
Viral heamorrhagic
septicemia virus
(VHSV)
Olive ﬂounder (4
e5 g)
1 time or boost
after 2w;
Gavage
Live recombinant
VHSV eGFP-NV
(DNV)
104 PFU/ﬁsh 25e60% 4 wpv i.m. (Kim et al., 2011)
105 PFU/ﬁsh 50e75%
2  105 PFU/ﬁsh 70e90%
Control 0%
Red-spotted
grouper nervous
necrosis virus
(RGNNV)
Convict grouper
(71.5 g)
1 time;
Gavage
RGNNV VLPs
produced in
S. cerevisiae
50 mg of puriﬁes
VLPs/ﬁsh
V: 100% 56 dpv i.p. (Wi et al., 2015)
C: 37%
Grass carp reovirus
(GCRV)
Grass carp (150 g) 21d;
Mixed with feed
f.i. E. coli expressing
capsid proteins
VP5-VP7
108 bacteria/feed
pellet
V: 90% 7 dpv i.p. (Lu et al., 2011)
C: 10%
Cyprinid Herpes
Virus-3 (CyHV3),
Spring Viremia
of Carp Virus
(SVCV)
Common carp
(500 g)
3d; followed by 2
boosts for 3d after
8d and 25d from
ﬁrst
administration;
Mixed with feed
SVCV-G and
CyHV3-ORF81
expressed in
L. plantarum
109 CFU/g feed V: 71% (SVCV) 5 dpv Oral (Cui et al., 2015)
C: 11% (SVCV)
Koi carp (350 g) SVCV-G and
CyHV3-ORF81
expressed in L.
plantarum
109 CFU/g feed V: 53% (CyHV3)
C: 8% (CyHV3)
Rock bream
iridovirus (RBIV)
Rock bream (7e8 g) 4 times, weekly
interval;
Mixed with feed
Major capsid
protein expressed
in Pichia pastoris
1  106 yeast cells/
2.5 g feed/ﬁsh
(250 mg
recombinant/ﬁsh)
V: 92% 10 dpv Bath (Seo et al., 2013)
C: 0%
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Table 1 (continued )
Pathogen Fish species Regime and
formulation
Antigen Dose Protection
(survival)
Time of
challenge
Challenge
route
Reference
Rock bream
iridovirus
Rock bream (10 g) 3 times, 10d
interval;
Mixed with feed
Major capsid
protein rMCP in rice
callus
10 mg lyophilized
calli powder/ﬁsh
80% 10 dpv Bath (Shin et al., 2013)
30 mg lyophilized
calli powder/ﬁsh
90%
Control 0%
Abbreviations: d: day(s); w: week(s); dpv: days post vaccination; wpv: weeks post vaccination, mpv: months post vaccination; h.i.: heat-inactivated; f.i.: Formalin-
inactivated; fy-i. formaldehyde-inactivated, UV-:. UV-inactivated; cohab: cohabitation; FIA: Freund's incomplete adjuvant; BW: body-weight; i.p.: intraperitoneal; i.m:
intramuscular.
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ing IPNV non-structural proteins, all showed promising levels of
protection. These results together suggest that enteric microbes
might be suitable vaccine vehicles. Live commensals might retain
their ability to colonize the gut environment and persist long
enough to deliver the antigen at mucosal surfaces. However, as a
result of the intrinsic ability to be tolerated by the host, on their
own they might not be sufﬁcient to trigger strong local responses.
In contrast, inactivated enteric pathogens might still be able to
diffuse through the mucus layer and adhere to enterocytes. By
doing so, theymight possibly provide inﬂammatory signals for local
immune reactions owing to the presence of Pathogen Associated
Molecular Patterns (PAMPs) triggering danger signals.
Production of vaccine antigens in plants including algae, po-
tatoes, tobacco or rice has been proposed as a viable approach for
the development of mucosal vaccines especially in veterinary
species, owing among others, to their relatively low production cost
and scalability (Liew and Hair-Bejo, 2015). Studies in mice
demonstrated the ability of rice-expressed proteins to effectively
deliver antigens to M cells and trigger local as well as systemic
response (Nochi et al., 2007). In ﬁsh, the ﬁrst report on an effective
oral vaccine produced in plants was reported only recently (Shin
et al., 2013). In the latter study, lyophilized rice calli of Oriza sat-
iva expressing the major capsid protein of Rock Bream Iridovirus
(RBIV) were mixed with the ﬁsh feed and were shown to confer
very good protection against a RBIV challenge.
Another expression system exploited for the generation of vac-
cine antigens is yeast. Antigens expressed and produced in yeast
beneﬁt from a similar protection from its host as antigens expressed
in bacteria. The wall of yeast makes the antigens less vulnerable to
degradation and decreases the need for further encapsulation.
Furthermore, yeast can easily be mixed with ﬁsh feed and might
even act as an adjuvant by its richness in b-glucans. When admin-
istered orally with the ﬁsh feed, the yeast Pichia pastoris expressing
the major capsid protein of RBIV conferred signiﬁcant protection
against RBIV challenge. However, protection was only evaluated
shortly after vaccination. The yeast expression system has also been
exploited for its ability to produce large quantities of Virus-Like
Particles (VLPs), which are multimeric protein complexes whose
shapemimic natural occurring virions. VLPs composed of the capsid
protein of the Red-spotted Grouper Nervous Necrosis Virus
(RGNNV) were produced in Saccharomyces cerevisiae (S. cerevisiae)
and conferred low but signiﬁcant protection against viral challenge
when administered orally (Wi et al., 2015).
Despite the many and promising approaches summarized in
Table 1 (and Supplementary Table 1), it is difﬁcult to draw general
conclusions on dose, vaccine type, and vaccine efﬁcacy since long-
term protection (>3 months) was not systematically addressed.
Most studies performed challenges 10e30 days after last vaccina-
tion, and only a few also assessed protection at later time points
(Azad et al., 1999; Bakopoulos et al., 2003; Bowden et al., 2002;Nayak et al., 2004; Siriyappagouder et al., 2014). Furthermore, in
most of the summarized studies, pathogen challenge was not per-
formed using the natural route of infection. It has already been
mentioned that oral vaccination can lead to increased serum IgM
levels, and that in some infections serum IgM levels correlated to
diseases resistance or susceptibility (Rombout et al., 1989; Tobar
et al., 2015). Nonetheless, it cannot be excluded that bypassing
the mucosa by directly injecting the pathogen into the peritoneal
cavity or muscle might also bypass crucial mucosal immune
mechanisms. As a consequence, the subsequent lack of activation of
local as well as systemic responses might lead to an underestima-
tion of vaccine efﬁcacy.5. Current strategies and efﬁcacy of experimental
encapsulated oral ﬁsh vaccines
In contrast to the abovementioned whole bacteria or yeast- and
plant-derived vaccines, more vulnerable vaccines such as DNA
plasmids, puriﬁed recombinant proteins and sub-unit vaccines
certainly need a form of protection to prevent breakdown and
ensure antigen uptake in the second gut segment of ﬁsh. In many
animal species, soluble, non-adherent antigens are generally found
to be taken up at low levels, if at all, and in the intestine, such
antigens commonly induce immune tolerance (Companjen et al.,
2006; Mayer and Shao, 2004; Neutra and Kozlowski, 2006). On
the contrary, enhanced mucosal immune responses were observed
when using antigens that could be retained at mucosal surfaces by
delivery in adherent polymers or were coupled to proteins that
themselves are adherent to epithelial surfaces (Companjen et al.,
2006; Gerdts et al., 2006; Neutra and Kozlowski, 2006).
It was clearly shown in mice and several other veterinary spe-
cies that micro-encapsulated vaccines have several advantages for
mucosal delivery. Microfold (M) cells are particularly accessible to
microparticles and actively transport them into Peyer's patches,
which consist of large clusters of lymphoid follicles localized in the
mucosa of the distal small intestine. Microparticles that are both
small (up to 1 mm diameter) and adherent to M cells are taken up
most efﬁciently (Frey et al., 1996; Mantis et al., 2000; Neutra et al.,
2001). Furthermore, speciﬁc glycolipids and protein-linked oligo-
saccharides on the apical surfaces of villus enterocytes, follicle-
associated enterocytes above Peyer's patches, and M cells play a
crucial role in antigen adherence (Frey et al., 1996; Lamichhane
et al., 2014; Mantis et al., 2000) Cells that are functionally equiva-
lent, but phenotypically distinct, from mammalian M cells have
been identiﬁed in the gut of Atlantic salmon (Fuglem et al., 2010).
The role of M-like cells in gut immunity together with gut barrier
function and anatomical construction are reviewed elsewhere in
this issue (Løkka and Koppang, 2016).
Given the presence of specialized antigen-sampling (M-like)
cells in the ﬁsh intestine, together with the already described
antigen-sampling ability of enterocytes and gut-associated
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can safely state that micro-encapsulation can be exploited to
further enhance uptake of the abovementioned inactivated bacteria
or yeast- and plant-derived vaccines (section 4). In this way vac-
cines that show a sub-optimal protection when delivered ‘naked’,
possibly due to high intestinal antigen breakdown, can be
improved upon encapsulation. An overview of the current experi-
mental approaches for the development of oral vaccines against
bacterial and viral pathogens using (bio)encapsulated antigens is
presented in Table 2 and will be discussed in this section.
Bio-encapsulation in live vehicles such as artemia, rotifer and
water ﬂeawas investigated for its suitability to vaccinate ﬁsh larvae
that do not yet feed on pelleted food (Table 2). Although some re-
ports describe the induction of protection after oral delivery of bio-
encapsulated vaccines for fry and larvae, protection was generally
assessed shortlyafterantigenadministrationpointingmore towards
an immunostimulatory effect of the vaccine. Furthermore,
maximumdosage of vaccination is restrictedby the daily feed intake
and encapsulation efﬁciency of the vaccine since the bio-
encapsulated vaccines are incorporated in the natural starter diet
of the ﬁsh fry or larvae. This efﬁciency strongly depends on the
chosen vehicle in combination with the state of the bacteria to be
encapsulated and their stability after bioencapsulation (Kawai et al.,
1989). Factors such as vaccine dose and time of exposure, especially
inyoung animals, are extremely crucial for vaccine efﬁcacy. As it will
be further discussed in section 7.2, these factors can certainly make
thedifference between induction of immune responses or tolerance.
Micro-encapsulation of vaccines in polymers such as chitosan,
Poly D,L-lactic-co-glycolic acid (PLGA), alginates, liposome, and
MicroMatrix™ are more practical and efﬁcient for juvenile and
older ﬁsh as they can be incorporated in the feed. The properties
and formulation of the aforementioned micro-encapsulation
methods have been extensively reviewed elsewhere (Plant and
Lapatra, 2011; Tafalla et al., 2013). Given this, we will concentrate
on a few studies that speciﬁcally focused on vaccine efﬁcacy upon
pathogen challenge (Table 2). Most evident is the success of
alginate-encapsulated live attenuated or avirulent enteric patho-
gens (e.g. Edwardsiella tarda, Staphylococcus iniae, Vibrio ssp) and
DNA vaccines against viruses. As further discussed later in section
7.3, such success might reside in the ability of the alginates to
protect the microbe and the plasmid while passing through the
digestive tract, and to diffuse through the gut mucus layer, thereby
reaching the enterocyte surface. Once in contact with the epithe-
lium, alginates might be actively taken up by antigen-sampling
cells and deliver the microbe or DNA plasmid. Enteric pathogens
will most likely have the intrinsic ability to activate local mucosal
responses, whereas DNA plasmids can then enter the nucleus and
trigger antigen expression in the host cell in a manner similar to
that triggered during a viral infection. The latter mechanism has
been previously described as the base of the great success of i.m.
injected DNA vaccines in ﬁsh (Lorenzen and LaPatra, 2005). The
efﬁcacy of DNA vaccines also conﬁrms that delivering nucleic acids
fulﬁls the requirements of closely mimicking antigen expression
and presentation during an intracellular pathogen infection. This in
turn will most likely trigger cellular as well as humoral immune
responses appropriate to the pathogen.
6. Rational immunological approach to oral vaccine design
for ﬁsh
There is no doubt that, independently of the administration
routes, vaccines that best mimic the natural pathogen infection and
trigger appropriate immune pathways against the pathogen, are
most effective; but how is this appropriate immune response
achieved?6.1. Triggering humoral responses
For pathogens against which an antibody-dependent systemic
humoral response is appropriate to confer protection, killed or
inactivated microbes, protein-adjuvant vaccines, virus-like parti-
cles (VLPs), or other subunit vaccines are sufﬁcient to trigger
adequate systemic immune responses. When inactivating the
pathogen or producing the subunits in heterologous expression
systems, care should be taken to assure that the antigenic epitope
against which the antibody response is directed remains intact.
Parenteral administration of such vaccines in the presence of ad-
juvants will in fact elicit antigen-speciﬁc neutralizing antibodies
that will protect the host upon natural infection. Brieﬂy, B cells can
directly recognize protein antigens and can be stimulated to pro-
liferate and secrete antibodies. In parallel, the adjuvant present in
the vaccine formulation will trigger the activation of local innate
immune cells, including Antigen Presenting Cells (APCs), through
recognition of viral PAMPs via Pattern Recognition Receptors (e.g.
TLRs, NLRs, RLRs). APCs will then upregulate the expression of pro-
inﬂammatory cytokines (i.e. IL-12, IFNa/b and TNFa) and co-
stimulatory molecules (i.e. CD80/86). These molecules are crucial
for the activation of cell-mediated immunity through antigen
presentation to CD4þ helper T cells via the MHC-II pathway. In turn,
CD4þ helper T cells, will differentiate to the Th1 subset under the
inﬂuence of the pro-inﬂammatory cytokines. Subsequent produc-
tion of IFNg by Th1 T cells will sustain antibody production, afﬁnity
maturation and memory formation of antigen-speciﬁc B cells. In
most mammals and in birds these antibodies, mostly of the IgG
isotype, will be able to ﬁx complement and will be present in the
circulation and peripheral immune organs.
Vaccines that exclusively elicit systemic humoral immunity,
however, might not be efﬁcacious against mucosal (enteric) path-
ogens, as parenteral immunization does not effectively elicit
mucosal responses (Neutra and Kozlowski, 2006). Pathogens that
undergo rapid antigenic variation will also not be stopped by vac-
cines exclusively inducing humoral immunity, as cross-protection
will not be achieved. Most importantly, pathogens against which
not only humoral but also cell-mediated cytotoxic T cell responses
are required (e.g intracellular microbes) will also not be affected by
vaccines that mainly elicit humoral responses. This last category,
which also includes most mucosal pathogens, comprises the largest
group of microbes against which effective vaccines are lacking in
most animal species. Perhaps it is not surprising that most target
pathogens are viruses and intracellular bacteria, with the exception
of few protozoan subspecies (e.g. plasmodium, trypanosomes) (Koff
et al., 2013).
6.2. Triggering cell-mediated T cell responses
To address the need to elicit systemic cell-mediated T cell re-
sponses in humans and several veterinary species, live attenuated
pathogens (bacteria or viruses) and non-replicating DNA plasmids
have been developed that are administered via the parenteral route
in the presence of strong adjuvants. One of the advantages of for
example live attenuated viruses is their ability to replicate in the
host but at much lower rate than the wild type virulent pathogen.
Such feature allows for the use of relatively low vaccine doses. Next,
and most importantly, vaccine replication in the host and the
presence of the adjuvant will trigger the activation of local innate
immune cells and APCs. This latter aspect is extremely crucial for
the activation of cell-mediated immunity through antigen presen-
tation to CD8þ T cells via the MHC-I pathway, as well as to CD4þ
helper T cells via the MHC-II pathway through cross-presentation.
The presence of viral particles as well as the expression of viral
antigens on the APC surface will also activate antigen-speciﬁc B
Table 2
Experimental approaches for the development of oral vaccines using (bio)encapsulated antigens.
Pathogen Encapsulation
method
Fish species Regime Antigen Dose Protection (%) Time of
challenge
Challenge route Reference
Bacteria
Vibrio anguillarum
(V.a.)
Bioencapsulation Ayu
(63 mg)
22d F.i. V. a. in water
ﬂea and rotifer
0.64 mg LPS/ﬁsh
detected
V: 92.4% 1 dpv Bath (Kawai
et al., 1989)C: 64.2%
Vibrio harveyi Alginates Rainbow
trout (15 g)
6 times, 1w
interval
Outer membrane
proteins (OMPs)
50 mg OMPs/ﬁsh/
day
V: 90% 12 wpv i.p. (Arijo et al.,
2008)C: 10%
Edwardsiella tarda
(E.t.),
Streptococcus
iniae (S.i.)
Alginates Japanese
ﬂounder
(12.4 g)
3d;
followed by
oral and
immersion
boost at 2 m
Attenuated E. t.
expressing
S. i. antigen Sia10
108 CFU/ﬁsh/day V: 82% (E.t.) 1 mpv Bath (E.t.);
i.p. (S. i)
(Sun et al.,
2012)C: 26% (E.t.)
V: 84% (S.i.)
C: 14% (S.i.)
108 CFU/ﬁsh/day,
8 h immersion
boost 107 CFU/ml
V: 76% (E.t.)
C: 22% (E.t.)
V: 86% (S.i.)
C: 26% (S.i.)
Edwardsiella tarda Alginates Japanese
ﬂounder
(10 g)
5d Avirulent E. tarda
strain ATCC 15947
109 CFU/ﬁsh/day V: 64e71% 5 wpv i.p. and bath (Cheng
et al., 2010)C: 14e18%
Edwardsiella tarda
(E.t.)
Alginates Japanese
ﬂounder
(9.6 g)
5d Pseudomonas
strain FP3
expressing E.t.
antigen Esa1
109 CFU/ﬁsh/day V: 56% 1 mpv i.p. (Sun et al.,
2010)C: 8%
Edwardsiella tarda,
Vibrio harveji
(V.h.)
Alginates Turbot
(14 g)
3d Live attenuated E.t.
expressing V.h.
DegQ soluble
antigen
108 CFU/ﬁsh/day V: 91% (E.t.) 1 mpv Bath (Hu et al.,
2011)C: 20% (E.t.)
V: 94% (V.h.)
C: 28% (V.h.)
Flavobacterium
columnare
Alginates Nile tilapia
(15.7 g)
7d F.i. F. columnare 2.65  1010 CFU/
ﬁsh/day
No protection 21 dpv Bath (Leal et al.,
2010)
Flavobacterium
psychrophilum
Alginates Rainbow
trout (1 g)
3 times for 7d,
followed by
11d standard
food
Live attenuated
F. psychrophilum
7.7  105 CFU/ﬁsh/ V: 8% 3 dpv Sub-cutaneous (Ghosh
et al., 2015)C: 0%
Aeromonas
hydrophila
Chitosan (600 nm);
alginate-chitosan
(1100 nm)
Indian
major carp
(100 g)
7d F.i. A. hydrophila 1  1010 CFU/ﬁsh/
day
V: 20% 7 wpv i.p. (Behera
and Swain,
2014)
C: 10%
Vibrio anguillarum Chitosan Asian sea
bass (10 g)
21d Porin gene, outer
membrane protein
OMP38 DNA
plasmid
50 mg plasmid/ﬁsh
total
V: 55% 1 dpv i.m. (Rajesh
Kumar
et al., 2008)
C: 10e15%
Vibrio
parahaemolyticus
Chitosan Black
seabream
(80 g)
3d Outer membrane
protein K in DNA
plasmid
50 mg plasmid/ﬁsh
total
V: 80% 21 dpv i.m. (Li et al.,
2013)C: 17%
Aeromonas
hydrophila
Liposome (5
e10 mm)
Common
carp (30 g)
3d F.i. A. hydrophila 10 ml of liposomes/
day
(33 mg/ml protein)
V:60e80% 22 dpv Intra-
subcutaneous
(Yasumoto
et al.,
2006b)
C: 55e100%
Aeromonas
salmonicida
Liposome Common
carp (350 g)
3 times, 2w
interval
Ultrasound-
inactivated
A. salmonicida
100mg/vaccination V: 84% 2 wpv Bath (Irie et al.,
2005)C: 63%
Piscirickettsia
salmonis
MicroMatrix Atlantic
salmon
(30 g)
10 times, 2d
interval
P. salmonis 1 1010 cells/g feed
(2% BW fed every
3d)
V: 80% 300 or 600
degree-dpv
i.p. (Tobar
et al., 2011)C: 10e20%
Stenotrophomonas
maltophilia
PLGA (2.2 mm) Channel
catﬁsh
(100 g)
3 times, 14d
interval
Ultrasone-
inactivated
S. maltophilia
50 mg/ﬁsh 43.3% 35 dpv i.p. (Wang
et al., 2011)100 mg/ﬁsh 65%
200 mg/ﬁsh 75%
Control 0%
Lactococcus garviae PLGA, alginates Rainbow
trout (20 g)
7d; booster at
61d
Formalin-
inactivated
L. garviae in PLGA or
alginate (Alg)
microspheres
1  1010 bacteria/
ﬁsh/day in PLGA or
alginate
microspheres (alg);
boost at 61d
PLGA: 68% 30 dpv i.p. (Altun
et al., 2009)Alg: 60%
C: 14%
PLGA: 50% 60 dpv
Alg: 44%
C: 10%
PLGA: 76% 90 dpv
(with
boost)
Alg: 72%
C: 14%
PLGA: 70% 120 dpv
(with
boost)
Alg: 68%
C: 14%
Viruses
Nervous necrosis
virus (NNV)
Bioencapsulation Orange
spotted
grouper
(18 dph)
2d Fy.-i. E. coli
expressing NNV
capsid protein in
Artemia
105 bacteria/
Artemia
V: 80e86% 35 dph i.p. (Lin et al.,
2007)C: 44e54%
Nervous necrosis
virus (NNV)
Bioencapsulation Orange
spotted
2d h.i. V. a. or E. coli
(E.c) expressing
8.3  104 CFU E. c/
Artemia (200/ﬁsh/
day)
25e45% 7 dpv i.p. (Chen et al.,
2011)
(continued on next page)
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Table 2 (continued )
Pathogen Encapsulation
method
Fish species Regime Antigen Dose Protection (%) Time of
challenge
Challenge route Reference
grouper
(30 dph)
NNV coat protein in
Artemia
4.1  106 CFU V. a/
Artemia (200/ﬁsh/
day)
52.5e87.5%
Control 2.5e42.5%
Infectious
haematopoietic
necrosis virus
(IHNV)
Alginates Rainbow
trout (3
e4 g)
1 time or boost
15d later
IHNV Glycoprotein
gene and promotor
region upstream of
interferon
regulatory factor 1A
gene
10 mg DNA (1 time) 22% 30 dpv Bath (Ballesteros
et al.,
2015a)
25 mg DNA (1 time) 30%
20 mg DNA (plus
boost)
46%
50 mg DNA (plus
boost)
56%
Control 0%
Infectious
pancreatic
necrosis virus
(IPNV)
Alginates (<10 mm) Rainbow
trout (1 g)
1 time IPNV capsid protein
VP2 gene in DNA
plasmid
10 mg DNA/ﬁsh V: 80e85% 15 dpv Bath (de las
Heras et al.,
2010)
C: 10e15%
V: 70e85% 30 dpv
C: 10e20%
Brown
trout (1.5 g)
1 time IPNV capsid protein
VP2 gene in DNA
plasmid
10 mg DNA/ﬁsh V: 85% 15 dpv
C: 10e15%
V: 85% 30 dpv
C:5e10%
Infectious
pancreatic
necrosis virus
(IPNV)
Alginates Rainbow
trout (1.5 g)
1 time IPNV capsid protein
VP2 gene in DNA
plasmid
10 mg DNA/ﬁsh V: 80% 15 dpv Bath (Ballesteros
et al.,
2015b)
C: 20e25%
Infectious
pancreatic
necrosis virus
(IPNV)
Alginates Rainbow
trout (1.5 g)
1 time (gavage)
or 3d (mixed
with feed)
IPNV capsid protein
VP2 gene in DNA
plasmid
10 mg/ﬁsh/day 1 time: 80% 15 dpv Bath (Ballesteros
et al., 2014)3d: 88%
C: 17%
1 time: 78% 30 dpv
3d: 82%
C: 17%
Infectious Salmon
Anaemia Virus
(ISAV)
Chitosan 333 nm
(NV) and 41.7 nm
(NV þ Adjuvant)
Atlantic
salmon
(70 g)
7d UV-i. ISAV (with
alphavirus
replicase DNA
vaccine as
adjuvant)
1  105 TCID50/ﬁsh 71% 450 UTA pv i.p. (Rivas-
Aravena
et al., 2015)
7 mg DNA/ﬁsh and
1  105 TCID50/ﬁsh
88%
Control 52%
Nodavirus (NV) Chitosan Asian sea
bass (10
e15 g)
1 day NV RNA2 capsid
protein gene in
DNA plasmid
100 mg plasmid/ﬁsh V: 85e90% 3 wpv i.m. (Vimal
et al., 2014)C: 50%
Cyprinid Herpes
Virus-3 (CyHV3)
Liposome Common
carp (25
e30 g)
3d F.i. CyHV3 20 ml liposomes/
day/ﬁsh
(20 mg tot. protein/
ml)
V: 77% 22 dpv Gill inoculation (Miyazaki
et al., 2008;
Yasumoto
et al.,
2006a)
C: 10%
Infecious
heamatopoietic
necrosis virus
(IHNV)
PLGA (500 nm
average, 200
e1000 nm)
Rainbow
trout (5 g)
4d or 8d IHNV Glycoprotein
gene in DNA
plasmid
22 mg plasmid DNA 17% 6 wpv i.p. (Adomako
et al., 2012)43 mg plasmid DNA 27%
Control 7%
22 mg plasmid DNA 17% 10 wpv
43 mg plasmid DNA 33%
Control 17%
Abbreviations: d: day(s); w: week(s); dpv: days post vaccination; dph: days post hatch; wpv: weeks post vaccination, mpv: months post vaccination; h.i.: heat-inactivated;
f.i.: Formalin-inactivated; fy-i. formaldehyde-inactivated, UV-:. UV-inactivated; cohab: cohabitation; FIA: Freund's incomplete adjuvant; BW: body-weight; i.p.: intraperi-
toneal; i.m: intramuscular.
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activation, antibody production and isotype switch in a manner
similar to the one described above (section 6.1). Altogether, such
response contributes to a full activation of effector humoral as well
as cell-mediated responses against viruses or other intracellular
pathogens. Interestingly, DNA plasmids, although not able to
replicate in the host cells, have been shown to effectively trigger
both arms of the immune system. Especially in ﬁsh, they have been
proven very successful and can be used at doses 100 times lower
than in larger mammals (Lorenzen and LaPatra, 2005; Meeusen
et al., 2007). Unfortunately, mainly due to legislative concerns,
only the DNA vaccine for vaccination of salmon again IHNV in
Canada is commercially available.
In ﬁsh, most of the aforementioned immune mechanisms are
believed to be generally conserved, although they have not been
investigated in details in all farmed ﬁsh species, and are reviewed
elsewhere (Gudding et al., 2014; Mucosal health in aquaculture,2015). Humoral as well as cell-mediated immune responses have
been associated with protection upon systemic as well as mucosal
vaccination in ﬁsh (Mutoloki and Jørgensen, 2014; Salinas, 2015).
Serum IgM levels have been associated with protection in several
vaccination strategies, especially against extracellular pathogens.
The relatively recent development of monoclonal antibodies in
ginbuna crucian carp and trout against the T cell markers CD8a and
CD4 (Toda et al., 2011, 2009) has allowed for a better character-
ization of T cell responses to infection and vaccination (Fischer
et al., 2013). Most of the signature cytokines associated to Th1,
Th2 and Th17 responses have been identiﬁed in ﬁsh, although their
full functional characterization is still underway in most relevant
ﬁsh species. Finally, the discovery of a novel immunoglobulin type
in 2005, named IgT (for Teleost (Hansen et al., 2005)), and the
generation of monoclonal antibodies against trout IgT, has provided
ﬁsh vaccinologists with a new tool to better characterize systemic
and mucosal responses (Salinas et al., 2011; Xu et al., 2016). A
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sponses identiﬁed and characterized thus far in ﬁsh has been
recently reviewed (Jørgensen, 2014;Mutoloki and Jørgensen, 2014).
A recent review focusing especially on the immunological mecha-
nisms following mucosal vaccination of ﬁnﬁsh is also available
(Munang'andu et al., 2015).
7. Triggering protective humoral and cell-mediated responses
upon oral vaccination
7.1. Targeting M-(like) cells and antigen presenting cells in the ﬁsh
gut
When antigens or vaccines are administered via the oral route
they are faced with the same host defence mechanisms as do
commensals and enteric microbes. Oral vaccines will have to sur-
vive the gastric environment, attacks by proteases or nucleases, and
stick to and penetrate the thickmucus to ﬁnally reach the epithelial
barrier. For these reasons relatively large amounts of antigens need
to be delivered orally, as it is impossible to exactly determine the
amount of antigen that is delivered to the epithelial layer. When
and if the vaccine will be in contact with the apical epithelium, it
will have to be actively taken up and delivered to the basal side. At
this side, the lamina propria, innate immune cells and speciﬁcally
APCs would process it. In mammals specialized antigen sampling
cells, M cells, are present in the follicle associated epithelium sur-
mounting Payer's patches but also on the apical part of the villus
epithelium (Mantis et al., 2000; Wang et al., 2014). Owing to their
location, antigen sampling ability, and structure, M cells play a key
role in exposing leukocytes in the lamina propria to the variety of
antigens and microbes present in the lumen of the gut. Further-
more, M cells efﬁciently sample luminal content (bacteria, viruses,
soluble microbial products or particulate antigens) and deliver it to
leukocytes on their basolateral membrane by using vesicles that are
transported through the cytosol (Neutra et al., 2001). M cells form a
pocket withinwhich leukocytes can aggregate. This pocket reduces
the distance between the apical and basal membrane thereby
increasing the efﬁciency at which antigens are delivered to
underlining leukocytes (Jang et al., 2004). Besides M cells,
specialized dendritic cells (DCs) extend protrusion through the
epithelial layer and directly sample antigens in the lumen (Owen
et al., 2013; Scott et al., 2011). As a result of their efﬁcient sam-
pling ability, strategic positions and specialized roles in activating
local immune responses, M cells and intraepithelial DCs have
become speciﬁc targets for vaccine delivery (Kim and Jang, 2014).
For example, a monoclonal antibody carrying a vaccine antigen has
been used to speciﬁcally deliver antigens to murine M cells (Nochi
et al., 2007), and several immunostimulatory molecules are
exploited to target DCs (Fujkuyama et al., 2012). In this way local
mucosal responses can be rationally triggered.
In salmon, a distinct population of M-like cells has been iden-
tiﬁed. These cells were found to be intermingled within the
epithelial layer, extend cytoplasmic protrusion to the luminal side
and be able to sample gold-BSAmicroparticles (Fuglem et al., 2010).
Although M-like cells speciﬁc markers have not yet been identiﬁed
in ﬁsh, salmon M-like cells show a staining similar to mammalian
M cells as were found positive for Ulex europaeus agglutinin (UEA-1
from gorse) and negative for wheat germ agglutinin (WGA). UEA-1
single-positive cells were only found deep in the mucosal folds of
the villi and not in the apical region. This suggests that they might
have a strategic position that allows them to interact with microbes
that gain access to the deeper area of the intestinal folds preventing
uptake and possible reaction to luminal (commensal) microbes.
Although leukocytes were not present in the basal pocket under-
neath the antigen-sampling cells, macrophage-like cells have beenseen associated to the basal side of M-like cells. In ﬁsh, both
enterocytes and intraepithelial macrophages have been shown to
play a role in antigen uptake in the second gut segment. Intra-
epithelial macrophages were shown to efﬁciently take up and
transport antigens especially when antigens where coupled to
enteric adhesion molecules (Companjen et al., 2006). Besides this,
the presence of motile non-resident macrophages that can poten-
tially transport antigens at peripheral sites has also been observed
(Rombout and van den Berg, 1989). Markers for ﬁsh macrophages
are available only in a few ﬁsh species (Ellett et al., 2010; Mulero
et al., 2008; Weyts et al., 1997). Nevertheless, they could be used
as a proof of concept to speciﬁcally target this putative APC in a
model ﬁsh species to demonstrate the suitability of cell-speciﬁc
antigen delivery approaches.
7.2. Induction of anergy or tolerance and antigen dose
Perhaps expected, but in mammals the majority of antigens or
microorganisms sampled from the lumen throughM cells or DCs do
not trigger a local immune response. The lack of responsiveness to
ingested or orally administered antigens is referred to as oral
tolerance, which is speculated to be the prevention of harmful re-
sponses to otherwise beneﬁcial food components and commensal
bacteria. This intrinsic homeostatic mechanism is the major
obstacle to overcome when designing oral vaccines. The mecha-
nisms leading to oral tolerance are still not fully understood, not
even in mammals. Nevertheless there is a general consensus that T
regulatory cells (Tregs) and tolerogenic DCs (tol-DCs) play an
important role in gut immunity and induction of oral tolerance
(Weiner and Wu, 2011). In mammals, Tregs express high levels of
the IL-2 receptors and may deprive other cell populations of this
growth factor by adsorbing IL-2. Tregs also express high levels of
the inhibitory receptor CTLA4 and through this compete with
normal T cells for co-stimulatory molecules on APCs. Finally, both
Tregs and tol-DC secrete high amounts of the anti-inﬂammatory
cytokines IL-10 and TGFb that greatly increase the threshold
required for leukocyte activation (Weiner and Wu, 2011). In fact,
under these conditions, an orally administered antigen that is taken
up and presented by DC to antigen-speciﬁc T cells will never trigger
an appropriate stimulatory signal, unless the antigen itself has the
ability to trigger strong pro-inﬂammatory responses. The latter
signals should then translate into the upregulation of MHC-II
molecules and co-stimulatory molecules (CD80/86) on the APC
surface as well as secretion of pro-inﬂammatory cytokines. In the
absence of pro-inﬂammatory signals and in the presence of IL-10
and TGFb, antigen presentation by non-activated APCs will trigger
the development of Tregs and render antigen-speciﬁc T cells
anergic or drive them to apoptosis (deletion) (Weiner and Wu,
2011). This in turn will contribute to depletion or unresponsive-
ness of the pool of antigen-speciﬁc T cells leading to tolerance upon
re-exposure to the same antigens.
From a vaccination point of view it is important to note that
induction of Tregs and anergy has been associated to antigen dose.
In mammals, high doses of orally administered antigens will induce
anergy and deletion of antigen-speciﬁc T cell whereas low antigen
dose will rather trigger Tregs development. In ﬁsh, although the
mechanisms of tolerance induction have not been systematically
addressed, antigen dose and route of administration have also been
associated to tolerance (Joosten et al., 1997; Maurice et al., 2004).
Given the difﬁculty to precisely quantify the amount of orally
administered antigen that is taken up at mucosal surfaces, it might
prove extremely difﬁcult to standardize the conditions at which the
vaccine will not induce tolerance. From an oral vaccine develop-
ment perspective, the vaccine antigen should therefore not only be
actively taken up and delivered to APCs in the lamina propria, but
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ﬁcient to break intestinal tolerance. In this respect, the use of strong
mucosal adjuvants or replicating vaccines will prove instrumental.
7.3. Mimicking pathogen entry and activation of mucosal responses
7.3.1. Live attenuated enteric pathogens as vaccine vectors
Live attenuated enteric pathogens, even in the absence of ad-
juvants, will have the ability to enter and replicate at the mucosal
surface and trigger appropriate mucosal responses, owing to the
presence of PAMPs that can trigger stimulatory signals. One of the
major hurdles is in the development of safe attenuated vaccines
that are least likely to revert to virulence. Attenuation by repeated
passages of viruses or bacteria in vitro does not always allow con-
trolling the number and sites of the mutations, making it more
difﬁcult to predict how likely the vaccine is to revert to the virulent
form. Furthermore, based on the nature of the pathogen, live
attenuated vaccines might not confer sterile immunity implying
that the vaccinated host will be carrier and shedder of the vaccine
pathogen. As discussed above, lack of sterile immunity might come
at great costs for the entire vaccinated and non-vaccinated
population.
The development of safe vaccines is of utmost importance when
considering animals, including ﬁsh, that are reared at high stocking
densities, under relatively stressful conditions and are transported
all over the world. In this situation vaccines should preferably
induce sterile immunity and not be harmful to any kind of animal,
the environment as well as the end consumer.
Due to the safety concerns, to date, one live bacterial vaccine has
been licensed for sale in aquaculture in Canada and Chile (Reno-
gen® only) and three in the US (Shoemaker et al., 2009). These
vaccines include Renogen® against bacterial kidney disease (BKD),
AQUAVAC-ESC® against enteric septicemia of catﬁsh, and AQUA-
VAC-COL® against columnaris disease of catﬁsh. A live viral hem-
orrhagic septicemia virus (VHSV) vaccine is available in Germany
(Gomez-Casado et al., 2011). Of interest the Renogen® vaccine is
based on cross-reactive immunity generated upon vaccinationwith
an environmental avirulent bacterium Arthrobacter (Ar.) davidanieli,
phylogenetically and antigenically related to Renibacterium salmo-
ninarum,which is the causative agent of BKD (Grifﬁths et al., 1998).
Unfortunately all aforementioned live attenuated vaccines are
delivered by immersion in catﬁsh fry one week post-hatch and are
not sufﬁciently protective when administered orally at this stage
(Lillehaug, 2014; Shoemaker and Klesius, 2014). A similar approach
was used to orally vaccinate Japanese ﬂounder against Edwardsiella
tarda (E. tarda). Very good protection upon i.p. and bath challenge
was found after oral administration of avirulent strains encapsu-
lated in alginate microparticles (Cheng et al., 2010). Moreover,
alginate encapsulated avirulent strains of E. tarda were used to
generate a cross-protective divalent oral vaccine against E. tarda
and Vibrio harveji or E. tarda and Streptococcus iniae and were found
to induce very good protection (Table 2).
Of note is the fact that E. tarda is an enteric pathogenwith a very
wide host and temperature range. For what discussed above, it
might retain its intrinsic ability to adhere to mucosal surfaces and
trigger strong mucosal responses even in the absence of adjuvants.
Using avirulent E. tarda as vehicle to express heterologous antigens
might prove a viable option against microbes for which attenuated
strains still show safety concerns or for which environmental
avirulent strains are not available. The safety level of avirulent or
attenuated E. tarda strains, together with serotype variability,
certainly needs to be systematically evaluated before it can ﬁnd its
commercial application. Regardless of the aforementioned chal-
lenges when developing live enteric pathogens as vaccine vehicles,
the large body of experimental work performed so far and theavailability of a few commercial vaccines that can be administered
by immersion, shows their great potential (Brudeseth et al., 2013;
Park et al., 2012). Similar approaches have been pursued using
other enteric pathogens such as E. coli and V. anguillarum that were
engineered to express the nervous necrosis virus (NVV) capsid
protein and were delivered as inactivated vehicles through artemia
(Table 2), (Chen et al., 2011; Lin et al., 2007). Although the length of
the vaccine administration as well as the duration of protection
need further optimization, the principle of using enteric pathogens
as oral vehicle seems very promising in ﬁsh as well.
7.3.2. Encapsulated DNA plasmid and activation of effective
mucosal responses
As summarized in Table 2, it appears that alginate-encapsulated
DNA plasmid might also fulﬁl most requirements for effective an-
tigen administration at mucosal surfaces followed by activation of
local immune responses. Considering their biochemical properties,
and possibly those of ﬁsh gut mucus, alginates might assure
plasmid protection, migration through the mucus layer, and efﬁ-
cient uptake by the epithelial layer. Once the plasmid enters the
cytoplasm, CpG motives present in the plasmid backbone might
deliver stimulatory signals acting as adjuvants. Once expressed by
host cells, the protein antigen encoded by the plasmid can be
recognized as a PAMP, activating local innate immune cells but also
antigen-speciﬁc B cells or NK cells through antibody-dependent
cell-mediated cytotoxicity (ADCC).
Of interest, alginate microspheres were used to successfully
vaccinate brown trout and rainbow trout against IPNV using VP2-
encoding DNA plasmid or against IHNV using glycoprotein (G)-
encoding plasmid (Ballesteros et al., 2015a, b; 2012; de las Heras
et al., 2010; Davison et al., 2003). Microspheres were generated
using a CaCl2 method that generally leads to relatively large parti-
cles (10e100 mm or larger). This size is much bigger than the one
considered to be most effectively taken up by M cells in mammals
(Frey et al., 1996). This suggests that cells other than antigen-
sampling M-like cells might be involved in the uptake of alginate
microparticles in ﬁsh. In our laboratory, an heterogeneous sus-
pension of alginate microparticles was generated using an alter-
native approach. Microspheres ranging in size between 1.6 and
9 mm containing a total of 20 mg of DNA plasmid encoding for the
SVCV-G protein (unpublished data) were delivered by oral gavage
to carp of 20 g. Immuno-histochemical analysis revealed strong G
protein expression throughout the epithelial layer of the second gut
segment at 14 days post-vaccine administration. Furthermore,
discrete macrophage-like cells and other leukocytes in the lamina
propria were also found to be strongly positive for G protein
expression. Our results, combined with the results in trout, suggest
that alginates, independently of the size, might be particularly
suitable to deliver antigens at mucosal surfaces in ﬁsh. They seem
to be effectively taken up or perhaps can directly fuse with the gut
epithelial membrane. Such efﬁcient antigen uptake by enterocytes
was observed previously (Rombout and van den Berg,1989) but can
however also pose a limitation to the efﬁcacy of oral vaccines: on
the one hand, persistence of the antigen in the enterocytes might
guarantee sufﬁcient antigen exposure and activation of local im-
mune responses, on the other hand however it might create con-
ditions leading to tolerance due to high local antigen dose if the
antigen persists for too long. Additionally, in ﬁsh kept at 20 C, the
intestinal epithelium in the second gut segment is completely
renewed within 10e15 days (Rombout et al., 1985; Stroband and
Debets, 1978). This time is of course temperature and ﬁsh species
dependent. In zebraﬁsh kept at 26 C, renewal was faster (7e10
days) in the second gut segment and took 5e7 days in the ﬁrst gut
segment (Wallace et al., 2005). Although the renewal period is
signiﬁcantly longer than observed in mammals (3e4 days), the
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cytes at the basal side of the epithelium, or taken up by intra-
epithelial macrophages. This might partly help explain why
relatively high plasmid doses need to be used upon oral adminis-
tration when compared to i.m. injection. Antigens might then have
to be delivered repeatedly, increasing the costs of oral DNA vacci-
nation. Furthermore, considering the importance of the antigen
dose in preventing the tilting of the balance towards induction of
oral tolerance, optimizing the time and dose of DNA plasmid de-
livery will be of utmost importance for successful oral DNA
vaccination.
7.3.3. Recombinant attenuated live vaccine vectors
Rather than relying on live attenuated pathogens, avirulent
strains, or DNA plasmids, a safer and rational attenuation of
candidate vaccine pathogens would be preferred. This could
circumvent risks linked to the potential reversion to virulence or
legislative concerns linked to the use of DNA vaccinated animals.
Attenuation can be achieved by engineering the pathogen by for
example selectively deleting metabolic pathway(s) or virulence
gene(s). Such approach also allows the generation of DIVA vaccines
facilitating the Discrimination of Infected from Vaccinated Animals,
by the addition of tags or other markers. DIVA vaccines are
particularly relevant in the veterinary vaccine industry to allow
transport and trading of vaccinated animals. As a trade-off, a great
deal of knowledge needs to be gathered about the pathogen in-
fectious cycle and genes function in order to be able to rationally
modify the pathogen. For large, complex viruses such as herpes-
viruses, or bacteria, this can greatly delay and increase the costs of
vaccine development. For pathogens containing a segmented
genome, such as inﬂuenza virus, engineering of genes in one or few
particular segments might not prevent resorting of genomic seg-
ments among inﬂuenza serotypes within the populations, thereby
quickly diluting out and losing the vaccine strain.
Rational pathogen attenuation has been attempted in ﬁsh as
well (Table 1). For example, live attenuated E. tarda mutants were
generated in which the alanine racemase gene and aspartase
semialdehyde dehydrogenase gene were knocked out, rendering
the mutants dependent on exogenous alanine and aspartate (Choi
et al., 2011). The mutants conferred good protection upon chal-
lenge with virulent strains when administered to Olive ﬂounder by
oral gavage. Live attenuated recombinant VHSV was generated by
removing the non-structural protein NV (DNV) and inserting eGFP
(Kim et al., 2011). Such attenuated strain was able to confer good
protection, in a dose-dependentmanner, when administered orally.
Despite the promising results, only few studies investigated the
efﬁcacy of recombinant attenuated vaccines for oral vaccine de-
livery. Still, long-term protection needs to be validated for the
abovementioned studies as challenge was performed relatively
shortly after last vaccination. Nonetheless, the use of enteric
pathogens, like E. tarda, proves again to be a viable strategy for oral
vaccine delivery.
8. Rational vaccine design and novel approaches for the
vaccines of the future
8.1. Live viral vectors as vaccine vehicles
Is it therefore at all possible to generate safe live vaccines? In the
last 30 years a great effort has been directed towards the identiﬁ-
cation of live viral or bacterial vectors that are not necessarily
derived from the pathogen against which the vaccine is developed.
For this purpose baculoviruses, lentiviruses, retroviruses, alphavi-
ruses and adenoviruses have received great attention. All these
vectors have several features in common: i) they can bemodiﬁed orare naturally non-pathogenic to the species in which they will be
used in; ii) they are able to deliver nucleic acids in eukaryotic cells,
allowing for vaccine antigen expression by the host cell itself; iii)
through viral pseudotyping, they can be designed to speciﬁcally
target the cells to be infected; iv) they have very straightforward
cloning and modiﬁcation strategy.
Due to their ability to insert their genome in the host chromo-
some, baculoviruses, lentiviruses and retroviruses have been
removed from the list of suitable vaccine vectors as they are
considered unsafe. Incorporation of viral genes in a random loca-
tion in the host genome can cause the onset of cancer (oncogenic
insertion), or in the case of species used for human or animal
consumption, the animals might be considered a Genetically
Modiﬁed Organism (GMO). The latter is a problem especially linked
to consumers' perception of safety; in fact, even though the foreign
gene might not necessarily incorporate in the gonads of the
vaccinated animals and therefore cannot be transmitted to the
progeny, consumers and legislative bodies are not willing to take
the risk. A very good case about how extremely successful vaccines
are currently not widely used on the market, is the one about DNA
vaccines in ﬁsh. As extensively discussed above, i.m. injection of
DNA plasmid or oral administration of alginate-encapsulated DNA
can be very effective in protecting ﬁsh against a variety of viral
pathogens. Unfortunately, with the only exception of the DNA
vaccine against IHN virus licensed in Canada for vaccination of
salmon, no other DNA vaccine is available on the marked for edible
species.
8.1.1. Alphaviruses
Alphaviruses are positive-sense, single-stranded RNA viruses
with a genome of approximately 11.5 kb in length that do not insert
their genome in the host chromosome. For this and for the relative
simplicity and ease of manipulation of their RNA genome, they also
represent interesting targets for vaccine vector development. Two
types of Alphavirus-based vectors have been designed (Vander
Veen et al., 2012) but none of them have so far been approved by
any regulatory agency for use in animals or humans. The ﬁrst vector
is based on the generation of a self-replicating RNA (replicon)
originating from a DNA plasmid also containing the sequence of the
gene of interest. The second vector is based on Alphavirus replicon
particles (RPs) that are single-cycle, propagation-defective particles
that carry RNA encoding for the gene of interest but are not able to
spread beyond the initial infected cells. As discussed above, the
second generation of Alphavirus RPs carrying RNA certainly have an
increased safety proﬁle with respect to DNA-based replicon RNA as
it does not require delivery of DNA sequences to the host. None-
theless, DNA-based salmonid alphavirus (SAV)-based replicon
vaccines encoding the infectious salmon anaemia virus (ISAV)
hemagglutinin-esterase (HE) have been shown to be extremely
effective when delivered i.m, whereas i.p. administration did not
provide the same protection (Wolf et al., 2014). Intramuscular de-
livery triggered strong local as well as systemic innate, humoral and
possibly cell-mediated responses, further supporting the suitability
of alphavirus-based vectors to trigger strong immune responses.
Another study also showed the broad temperature range
(4Ce37 C) and tropism of the SAV-based replicon as it was
functional in ﬁsh, mammalian and insect cells in vitro as well as in
shrimps in vivo (Olsen et al., 2013). The level of heterologous pro-
tein expression by the SAV-based replicon is however lower than
observed in mammalian replicon-based systems. To date, such
vectors have not been tested for oral delivery. For this reason it will
be interesting to raise their safety proﬁle by developing Alphavirus
replicon particles that could deliver RNA rather than DNA.
Furthermore, based on their proven ability to trigger the immune
system of ﬁsh, immunity to the vaccine vector will also have to be
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8.1.2. Adenoviruses
Taking into account the abovementioned safety considerations,
adenoviruses are currently at the vanguard of live viral vectors for
use in humans and veterinary species (Appaiahgari and Vrati,
2015). Adenoviruses are medium-sized, non-enveloped double-
stranded DNA viruses. Adenoviruses have been isolated from all
vertebrate species, including ﬁsh (Davison et al., 2003), and are
known to causemild to severe respiratory disease inwarm-blooded
animals and enteric/renal diseases in aquatic animals. The best
characterized adenoviruses are those of mammalian and avian
origin (Bangari and Mittal, 2006). In ﬁsh, only one representative
has been isolated from white sturgeon and has been temporarily
assigned to a separate new genus (Kovacs et al., 2003). Advantages
of adenoviral vectors include their large packaging capacity (>8 kb),
high titres and high levels of transgene expression when placed
under a strong promotor. Moreover, they are able to target a broad
range of dividing and non-dividing cell types with almost 100%
efﬁciency. Unlike lentiviruses or retroviruses, adenoviruses do not
integrate into the host genome which greatly increases their safety
proﬁle.
Good examples of the great success of adenoviruses as vaccine
vectors are the recently developed experimental vaccines against
Ebola virus (Gilbert, 2015), malaria (Ogwang et al., 2015; Schuldt
and Amalﬁtano, 2012), Respiratory Syncytia Virus (RSV) (Green
et al., 2015) Foot-and-Mouth Disease (Porta et al., 2013). They are
generally based on a combined vaccination regime starting with
prime vaccination with a modiﬁed non-human adenovirus, fol-
lowed by booster vaccination with a modiﬁed poxvirus (mostly
Modiﬁed Vaccinia Ankara (MVA)). The adenovirus vector, very
effectively triggers strong humoral and cell-mediated responses to
the vaccine antigen but also to the adenovirus vector itself.
Therefore booster vaccination with an heterologous vector is
required to prevent elimination of the adenovirus-based vaccine in
primed vaccinated individuals.
The discovery and pioneering work performed on mammalian
and avian adenoviruses, combined with the presence of cold-
blooded adenoviruses, represents a novel, unexploited strategy
that could be undertaken by ﬁsh vaccinologists for future vaccine
development. For this, the further characterization of the currently
identiﬁed adenovirus genome, the search for additional strains
infecting ﬁsh species other thanwhite sturgeon, and the generation
of tools for their genetic manipulation, will be essential to ascertain
the potential of adenoviruses as effective vaccine vehicles also in
ﬁsh.
9. Improvement of currently suboptimal oral vaccines:
mucosal adjuvants
Non-replicating antigens such as soluble proteins, plasmid DNA
or killed pathogens are poorly immunogenic when delivered orally.
Moreover, they generally induce tolerance because of their inability
to trigger appropriate inﬂammatory stimuli and costimulatory
signals. Therefore, the use of potent mucosal adjuvants can greatly
enhance the efﬁcacy of such suboptimal vaccines. The use of novel
adjuvant formulations for improvement of ﬁsh vaccine efﬁcacy has
been extensively reviewed elsewhere (Tafalla et al., 2013), therefore
in this section we will focus on mucosal adjuvants that can spe-
ciﬁcally enhance oral vaccine efﬁcacy.
The relative success of the few commercial oral vaccines for ﬁsh
can perhaps be partly attributed to their protective encapsulation
method: antigen protective vehicle (APV) byMSD orMicroMatrix™
by Centrovet (Brudeseth et al., 2013). Even though these vehicles
might provide stimulatory signals, they are obviously not sufﬁcientto trigger a strong memory response (Tobar et al., 2015) as the oral
vaccines alone are not sufﬁcient to provide long-lasting protection.
These vaccines however, can be used as a base to start testing novel
combinations of mucosal adjuvant-vaccine antigens. Suboptimal
vaccines could be administered in combination with conventional
adjuvants or molecules that have been shown to exert strong
immunostimulatory activities also in ﬁsh and are therefore able to
trigger danger signals. Examples of the latter type include entero-
toxins or PAMPs such as: the non-toxic part of the Escherichia coli
heat-labile enterotoxin (LTB), cholera toxin b-subunit (CTB),
polyI:C, beta-glucans, bacterial ﬂagellin or CpG motifs.
9.1. Conventional adjuvants
Some of the adjuvants generally used for injection vaccination in
humans or veterinary species (i.e. alum and Freund's incomplete)
have also been tested in ﬁsh in combination with oral vaccines
(section 4 and Table 1). Although the reports showed the applica-
bility of using standard injection vaccine adjuvants in an oral
vaccination strategy, possible side effects need to be assessed.
Other promising adjuvants components considered in experi-
mental human and veterinary vaccines are liposomes, saponins (e.g
Quil-A, QS-21) or highly immunogenic immune stimulating com-
plex (ISCOMS). At this moment, Pharmaq is studying the intro-
duction of the latter adjuvants in commercialised ﬁsh vaccines
(Tafalla et al., 2013). Two studies already investigated the efﬁcacy or
liposomes for oral vaccination of ﬁsh (Table 2). The ﬁrst study
showed successful oral vaccination of carp against CyHV-3 using
liposome-encapsulated formalin-inactivated (f.i) CyHV-3 (Miyazaki
et al., 2008; Yasumoto et al., 2006a). The second study, showed
more variable degrees of protection against A. hydrophila using
liposome-encapsulated f.i. A. hydrophila (Yasumoto et al., 2006b). In
both cases, long term protection and the underlining protective
mechanisms have not been investigated in details. The saponing
Quil-A was found to increase systemic antibody levels against the
model antigen Human GammaGlobulin (HGG) after oral delivery to
Mozambique tilapia but protection after challengewas not assessed
(Jenkins et al., 1991).
Additional adjuvants that are included in licensed human and
veterinary vaccines and can be used for both, parenteral or mucosal
administration include: MF59® (oil-in-water emulsion), a
squalene-based adjuvant system 03 (AS03®) and AS04® (mono-
phosphoryl lipid A (MPL-A)þ alum) (Savelkoul et al., 2015). They all
have been shown to effectively induce humoral as well as cell-
mediated responses to various degrees, at least when adminis-
tered via the parenteral route. Squalene is a cholesterol precursor
that is added to adjuvant emulsions (i.e. MF59 and AS03) and was
shown to enhanced antigen uptake by DCs. Local reactions and its
persistence in oil residues however, drive the demand for alterna-
tives. Non-toxic MPL-A, derived from LPS, is a TLR4-targeting
adjuvant that was shown to greatly enhance APCs activity as well
as T and B cell memory responses. Muramyl dipeptide (MDP) pre-
sent on bacterial cell walls is currently included in various experi-
mental formulation and, similarly to MPL-A, is a strong activator of
APCs and of cellular responses. To date, none of the above-
mentioned licensed adjuvants or their components have been
tested for oral vaccine delivery in ﬁsh. Considering their full char-
acterization, safety proﬁle, and most of all, their ability to induce
humoral and cell-mediated responses, the aforementioned adju-
vants or their components, represent promising novel tools to
further improve currently insufﬁcient oral vaccines.
9.2. Enterotoxins as strong mucosal adjuvants
To improve delivery and uptake of antigens to the hindgut,
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the ability to induce strong inﬂammatory signals. For example,
fusion of Green Fluorescent Protein (GFP) to LTB (LTB-GFP) led to
increased GFP uptake in the carp mucosa and enhanced GFP-
speciﬁc serum antibody levels. While almost no GFP was detected
after non-LTB-fused GFP administration, high levels of GFP were
detected in enterocytes and macrophage-like cells after delivery of
LTB-GFP (Companjen et al., 2006). In earlier studies, the enteric
protein CTB was found to increase systemic antibody levels against
the model antigen Human Gamma Globulin (HGG) after oral de-
livery to Mozambique tilapia (Jenkins et al., 1994). Enterotoxins
hold great promise as mucosal adjuvants as very little amounts
have been shown to trigger strong mucosal responses in humans
and in veterinary species, including ﬁsh. Modiﬁed subunits have
been developed that retain their immunostimulatory capacity
while limiting the exacerbated inﬂammatory response (Elson and
Dertzbaugh, 2005; Lycke, 2005). These toxins are effective as
mucosal adjuvants, presumably because they retain the ability to
penetrate the mucus layer, are taken up by M cells or mucosal DCs,
and ultimately activate key innate signalling pathways. Activated
DCs in turn orchestrate adaptive immune responses that are
appropriate for defence against live pathogens. Given the already
ascertained ability of these molecules to enhance uptake by intra-
epithelial macrophages, it will be interesting to evaluate their
possible uptake by the recently described ﬁsh M-like antigen-
sampling cells and follow their faith within the vaccinated ani-
mal. This information might certainly contribute to a better un-
derstanding of the protectivemechanisms that need to be triggered
to elicit protective mucosal responses.
Perhaps acting in a similar manner as enterotoxins, a new
microparticle-based oral adjuvant containing LPS was described. In
this study, LPS from meningococcus bacteria was found to signiﬁ-
cantly induce IgM production and protection against A. hydrophila
in African catﬁsh after oral administration (Perez et al., 2013). LPS
molecules, similarly to enterotoxins, might in fact retain the ability
to trigger strong local responses and enhance the efﬁcacy of sub-
optimal inactivated vaccines.
As discussed previously, not only enterotoxins but also enteric
pathogens themselves (e.g. E. tarda, V. anguillarum, E. coli, Y. ruckeri),
either as live vehicles or as inactivated pathogens, can provide
adequate stimulatory signals and act as adjuvants for currently
suboptimal oral vaccine formulations.
9.3. Molecular adjuvants
Although studies show the potential of using molecular adju-
vants such as DNA plasmid-encoded molecules or RNA-based
vectors, their use in oral vaccination for ﬁsh is very limited. For
example, Alphavirus replicon vaccines have been widely used in
mammalian vaccines and are known to activate the innate and
adaptive immune system at various levels. This approach was also
used in an oral DNA vaccine for Atlantic salmon against Infectious
Salmon Anaemia Virus (ISAV). It was observed that addition of the
alphavirus replicon DNA sequence signiﬁcantly increased protec-
tion upon ISAV challenge when compared to the oral DNA vaccine
without the molecular adjuvant (Rivas-Aravena et al., 2015). The
large number of dsRNA sequences accumulated upon delivery of
the Alphavirus replicon might contribute to the observed adjuvant
effect.
A chitosan-encapsulated DNA vector encoding heat shock pro-
tein 70 (hsp70) of the protozoan Cryptocaryon irritans (C. irritans)
was found to signiﬁcantly increase survival of orange spotted
grouper when administered orally along with a DNA plasmid
encoding the immobilization antigen (iAg) of C. irritans. This study
not only showed that oral DNA vaccination is also effective againstextracellular parasites, but also that heat shock proteins can act as
molecular adjuvants when administered orally (Josepriya et al.,
2015).
Several cytokines and chemokines have been tested as molec-
ular adjuvants in injected DNA vaccines (Tafalla et al., 2013) For
example, strong adjuvant effects have been described for ifna, ifnb
and ifnc in Atlantic salmon that were vaccinated with a suboptimal
DNA vaccine against ISAV. Besides increased protection, signiﬁ-
cantly higher antibody levels and expression of several B- and T-cell
markers was found in the muscle, indicating an interferon-induced
inﬂux of leukocytes to the site of injection (Chang et al., 2015).
Other cytokines such as Il8 and Il1b (peptides) have also been used
but never in combination with oral vaccine delivery. Given the
necessity to trigger strong inﬂammatory signals that are able to
overcome the high tolerogenic threshold of the gut environment,
cytokines such as Il12, Ifng or Tnfa could also be used alone or in
combination. Most of these cytokine induce activation of APCs by
triggering the upregulation of pro-inﬂammatory cytokines, MHC-II
and CD80/86 co-stimulatory molecules. For this reason, they could
be used in combination with inactivated/killed pathogens that
alone trigger little activation of APCs.
9.4. PAMPs as mucosal adjuvants
Great advances have been made in ﬁsh research in trying to
identify and characterize several Pattern Recognition Receptors
(PRRs), scavenger receptors, C-type lectins etc, because these in
fact, represent the targets for rational adjuvant design.
In ﬁsh, PAMPs such as bacterial ﬂagellin (targeting TLR5) or CpG
motives (potentially targeting TLR9), have been shown to exert
strong immunostimulatory activities and to have adjuvant activ-
ities when administered with suboptimal parenteral vaccines, as
reviewed in (Tafalla et al. (2013)). Flagellin, especially from enteric
pathogens (i.e. Vibrio ssp, Salmonella ssp), holds great promise. In
fact, similar to enterotoxins, it has the ability to withstand the
gastric environment and the potential to target receptors on leu-
kocytes at mucosal surfaces, hereby triggering the necessary cos-
timulatory signals on APCs. CpG motives, either incorporated in the
plasmid backbone of DNA vaccines or administered along with
antigens, have been shown to have signiﬁcant immunostimulatory
activities. Their effects are, however, sequence- and species-
dependent (Pietretti and Wiegertjes, 2014) suggesting that the
choice of CpG motives has to be tailored to the ﬁsh species. This
implicates that, when administered to different ﬁsh, the same
vaccine antigen might have to be combined to different CpGs in
order to exert its adjuvant effect. Despite their extensive charac-
terization in vitro, and in vivo upon parenteral administration of
antigens, the use of both ﬂagellin and CpGs as mucosal adjuvants
awaits further characterization.
Among the most promising immunostimulants that could be
used as mucosal adjuvant in oral vaccine formulations, beta-
glucans are perhaps the best known and characterized (Bonaldo
et al., 2007; De Smet et al., 2013; Ogier de Baulny et al., 1996;
Selvaraj et al., 2006, 2005; Skov et al., 2012; Petit & Wiegertjes,
2016). Beta-glucans are easily incorporated into the ﬁsh standard
feed, making them suitable candidate adjuvants for oral vaccina-
tion. Adjuvant activities of beta-glucans have been demonstrated in
ﬁsh most often in combination with i.p. vaccination against bac-
terial diseases (Fredriksen et al., 2011; Suanyuk and Itsaro, 2011).
Their potential in oral vaccination, however, has not yet been
investigated.
In addition to the use as an immunostimulant, beta-glucans can
also function as a vehicle to encapsulate and protect antigens.
Although this has not yet been exploited for ﬁsh vaccines, sub-
cutaneous injection of mice with OVA-loaded beta-glucan
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compared tomice injectedwith OVA absorbed to the adjuvant alum
(Huang et al., 2010). The potential use of GPs in oral vaccinationwas
investigated using human intestinal cell lines (Caco-2 and HT-29)
and mice (De Smet et al., 2013). It was found that in vitro GP-OVA
complexes were internalized by Caco-2 and HT-29 cells and that
the complexes did not affect cell viability. Internalization induced
an increased expression of il23p19, il8, and a downregulation of
tgfb. The above mentioned results show the adjuvant potential of
GPs as vaccine vehicle but future research is necessary to test their
applicability for ﬁsh vaccines.
Another well-known and widely used adjuvant is poly-
inosinic:polycytidylic acid (poly I:C), which has been used in mul-
tiple ﬁsh vaccination studies by injection vaccination but not yet as
an mucosal adjuvant. In mammals, poly I:C is most often delivered
in nano- or microspheres because of its vulnerability to serum
nucleases and because high doses of systemic poly I:C are toxic and
can induce autoimmunity (de Clercq, 1979). In ﬁsh, co-delivery of
chitosan-encapsulated poly I:C and inactivated whole VHSV by i.p.
injection was found to induce signiﬁcant protection in zebraﬁsh
against a challenge with VHSV. However, there was no signiﬁcant
difference in survival between groups vaccinated with or without
poly I:C as adjuvant (Kavaliauskis et al., 2015). Similar protective
effects were found when zebraﬁsh were co-vaccinated with the
VHSV-G protein and poly I;C (Kavaliauskis, manuscript in prepa-
ration). Poly I:C can also be combined with other adjuvants to
further enhance its immunostimulating properties. Combinations
of poly I:C and CpG were found to increase protection in Atlantic
salmon against SAV when combined with i.p. injection of an inac-
tivated SAV vaccine (Thim et al., 2014, 2012). Altogether, the above
studies show the potency of poly I:C as an adjuvant for ﬁsh vac-
cines. However, its use as an adjuvant for oral vaccination is yet to
be evaluated.
9.5. Plant-based proteins as immunostimulants to break mucosal
tolerance
Plant-based proteins, including soy bean meal and concentrates
thereof, are becoming increasingly important as protein source to
reduce ﬁshmeal content. However, it is known that the substitution
of ﬁshmeal with soy bean meal may have adverse effects such as
induction of intestinal lesions and subacute enteritis (Chikwati
et al., 2013; Couto et al., 2014). Enteritis leads to a widening of
the lamina propria and a subsequent inﬂux of immune cells. The
inﬂux of immune cells interferes with the barrier function of the
intestine and increases the ease of pathogens or antigens to pass
the intestinal barrier (Knudsen et al., 2008).While intestinal lesions
and severe enteritis needs to be prevented, soy bean meal might be
used as a feed additive to increase vaccine antigen uptake by
increasing permeability of the intestinal wall. This possibility was
evaluated in rainbow trout orally vaccinated with PLGA nano-
spheres containing a DNA vaccine against IHNV. Fish were fed diets
either containing 35% soy bean meal or 35% soy bean concentrate
but no signiﬁcant differences were found in nanoparticle uptake or
survival when being challenged ten weeks after vaccination
(Adomako et al., 2012). Since severe enteritis induced by high soy
bean meal concentration leads to endocytosis block rather than an
increase in uptake in a species-speciﬁc manner, care should be
taken to ﬁnd an optimal low dose for every ﬁsh species and size
(Uran et al., 2008).
Altogether, a rational selection of enteric (live) vectors or
encapsulationmethodsmight aid the development of neweffective,
and the improvement of current suboptimal, oral vaccines for ﬁsh.
Moreover, it will certainly provide amatrix of tools when combined
with a more targeted selection of mucosal adjuvants based on theirimmunostimulatory ability and afﬁnity for the gut environment.
10. Consideration on the nature of the ﬁsh and its
environment
Oral vaccine development in ﬁsh might present an additional
degree of complexity when considering the vast number of
cultured ﬁsh species and the diversity within. Therefore, different
ﬁsh species may require a different strategy for the development of
oral vaccines, even against the same pathogen. Major differences in
gut morphology as well as intestinal environment can be found
between stomachless ﬁsh and ﬁsh with a stomach, and between
carnivorous, herbivorous and omnivorous ﬁsh species.
Oral vaccination of ﬁsh that do not have a stomach may require
less protection of the antigen since they are not exposed to the
harsh environment and low pH of the stomach. However, factors
others than stomach pH are involved and even within the group of
ﬁsh that possess a stomach, large differences exist. For example,
ﬁsh with a thin stomach wall, like rainbow trout, have high stom-
ach acidity because they are more dependent on pH than onmuscle
strength for food kneading and breakdown. This is in contrast to
ﬁsh with a thick muscular stomach wall, like African catﬁsh, that
are better able to knead food and are therefore less dependent on
stomach pH for food breakdown (Weber, 2014).
Carnivorous ﬁsh species have higher protease activity compared
to herbivorous and omnivorous species. Non-carnivorous ﬁsh
might have high a-amylase activity, since plant materials are
difﬁcult to digest. It is important to gain knowledge on the ﬁsh
intestinal tract and its environment tomake an estimate of the level
of stress that the vaccine will encounter. Depending on the esti-
mated degree and source of breakdown, an antigen protection or
encapsulation technique can be chosen or designed. Besides
feeding preferences, differences in digestion enzymes and intesti-
nal environment are caused by several other factors including age
of the ﬁsh, temperature and season (Chakrabarti et al., 1995;
Kolkovski, 2001).
In humans, success or failure of mucosal vaccines in Latin
American, European, American individuals versus African patients
has been largely ascribed to differences in microbial compositions
(Valdez et al., 2014). In mice it has been shown that gut microbiota
largely inﬂuences the development of an healthy mucosal immune
system and most importantly that oral tolerance could not be
induced in the absence of signals derived from the gut ﬂora (Bauer
et al., 1963; Hapfelmeier and Macpherson, 2010; Hill and Artis,
2010; Kiyono et al., 1982; Sudo et al., 1997). Studies have demon-
strated that also in zebraﬁsh the composition the gut microbiota
plays a crucial role of in the onset of enterocolitis (Brugman et al.,
2009) and recent reviews have summarized how also in teleost
ﬁsh a delicate arm race between the host, commensals and path-
ogens is taking place at mucosal surfaces (Gomez et al., 2013).
Therefore, considering the immense heterogeneity of ﬁsh species,
their environment and eating habits, a careful consideration of the
enterotypes (gut microbiota community proﬁles) of aquaculture
species should also be taken into account when developing oral
vaccines.
While antigen coating or encapsulation can be the key to ensure
sufﬁcient antigen delivery to the hindgut, the biochemical prop-
erties of the encapsulation vehicle can strongly inﬂuence the de-
gree of uptake and antigen release. Consequently, choosing a
suboptimal antigen coating or encapsulation system can have
detrimental effects on the efﬁcacy of the delivered vaccine. As an
example, oral vaccination of rainbow trout against IHNV using
PLGA-microencapsulated DNA vaccine resulted in low protection,
while uptake of the microspheres was signiﬁcant. This apparent
discrepancy was found to be caused by the property of PLGA to not
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nationwas performed (Adomako et al., 2012). This study shows the
importance of choosing an encapsulation method whose charac-
teristics match with the environment of the ﬁsh.
Last but not least, in experimental vaccination and challenge
experiments of ﬁsh, temperature might be a key element deter-
mining the level of success. It is commonly known that the ﬁsh
immune system is rather slow compared to mammals, especially
that of ﬁsh living in cold environments. Besides temperature,
changes in water type and culturing conditions will also play a role
as for example salmon having to move from fresh to salt water
conditions and from tanks to sea cages. Only few studies system-
atically addressed the effect of temperature on vaccine efﬁcacy. For
example, vaccination of coho salmon against V. anguillarum at
temperatures ranging from 3.9 to 20.6 did not lead to signiﬁcant
differences in vaccine efﬁcacy as all groups showed very good
protection (Fryer et al., 1978). On the contrary, a temperature-
dependent effect was observed on the protective innate and
adaptive mechanisms induced upon i.m. DNA vaccination of
rainbow trout against VHSV. While the vaccine protected the ﬁsh
well at temperatures of 5, 10 and 15, no neutralizing antibodies
and a delayed mx3 expression were observed only in ﬁsh vacci-
nated at 5 (Lorenzen et al., 2009).
Altogether, given the vast diversity of ﬁsh species, heterogeneity
of their environment and culturing conditions, testing the vaccine
in the target species and under ﬁeld conditions will prove to be
crucial to ﬁnally validate vaccine efﬁcacy.
11. The zebraﬁsh as animal model for aquaculture animals
Vaccine validation should certainly be performed in the species
of interest and under conditions that best resemble the natural
rearing conditions and environment. Still, the use of ﬁsh models
might help speed up part of the process linked to the character-
ization of the vaccine and of the immune response of the host. In
the past 20 years, the small zebraﬁsh has managed to climb the
pyramid of animal models commonly used for biomedical research
in humans. Despite its established reputation in the biomedical
ﬁeld, zebraﬁsh has been largely underestimated and poorly used as
a model in the aquaculture ﬁeld. The availability of numerous
transgenic ﬁsh lines, including those speciﬁcally marking IgM þ B
cells, T cells, macrophages, or neutrophils, creates an unique op-
portunity to investigate the real-time kinetics of cell recruitment,
proliferation andmigration in response to speciﬁc vaccine antigens.
Double transgenic and reporter ﬁsh lines for speciﬁc cytokines or
chemokines are also available. These lines might help elucidate
which cell types express which molecules, when and where, in
response to antigens or adjuvants. This type of analysis is in general
rarely possible in most ﬁsh species due to the scarcity of antibodies.
The use of transgenic ﬁsh lines in combination with labelled
antigensmight help predict the faith of for example orally delivered
antigens and the relative contribution of speciﬁc cell types in the
uptake, presentation and activation of the immune response. A
detailed reviewof zebraﬁsh gut physiology and its potential use as a
model to study intestinal responses is reviewed elsewhere in this
issue (Brugman, 2016). Fluorescently labelled inactivated or live
vectors could be easily traceable in zebraﬁsh. Delivery and uptake
of (encapsulated) antigens could be monitored in all gut segments
and suitability of various encapsulation methods, based on size or
stability, could be performed in real-time. Chemical ablation of
speciﬁc cell types is also possible in zebraﬁsh (Gray et al., 2011),
allowing the determination of the role of speciﬁc leukocytes in the
response to the vaccine. For example, the ultimate proof thatM-like
sampling cells transport and deliver antigens to leukocytes in the
lamina propria could come from the generation of novel transgeniczebraﬁsh lines, as soon as M-like cell markers are identiﬁed in ﬁsh.
Besides the availability of transgenic lines, several mutants are also
available. For example, Il10/ knockout zebraﬁsh are available and
could be used to investigate the role of Il10 in the onset or main-
tenance of gut tolerance. Furthermore, live imaging is not only
limited to the transparent larval stages, but with the combined use
of for example two-photon microscopy and casper mutant ﬁsh that
lack pigmentation, it can be extended to the juvenile and adult ﬁsh
as well.
Despite the many advantages of the zebraﬁsh model, including
the ones mentioned above, the use of zebraﬁsh as a model for
aquaculture species poses some limitations. Zebraﬁsh is a cyprinid
ﬁsh living in fresh waters at an optimal temperature of 27 and is a
stomachless, omnivorous ﬁsh. Due to these characteristics, the
zebraﬁsh is certainly a suitable pre-screening model for cyprinids
and some fresh water ﬁsh. In contrary, it might be less suitable for
other commercially relevant species, including salmon, trout,
turbot, seabream, or sea bass. As discussed above, the microbiota
plays an extremely crucial role in inﬂuencing gut development,
homeostasis as well as induction of tolerance. As a consequence the
microbiota and the gut environment will be extremely different
between omnivores and carnivores. Nevertheless, zebraﬁsh can
provide the proof of principle of the validity of novel approaches
andmay help accelerate the selection of antigens, adjuvant, vaccine
vehicles or encapsulation methods, which without doubt, will ul-
timately have to be validated in the species of interest.
12. Concluding remarks
Based on the status of oral vaccines in humans and veterinary
species, there is no doubt that the generation of safe and efﬁcacious
oral vaccines is among one of the most difﬁcult tasks of immu-
nologists. This is illustrated by the very limited number or oral
vaccines approved for use in humans and the slightly larger num-
ber approved for use in poultry, pigs and cattle. In this respect ﬁsh
are not lagging much behind, with 5 oral vaccines available on the
market. These vaccines however, are against only a very limited
number of pathogens and are available for an even smaller number
of ﬁsh species. When considering the vast diversity of cultured ﬁsh
species and their pathogens, the current oral vaccines are by far
insufﬁcient to fulﬁl themarket requirements. Such species diversity
is in fact larger than the diversity in species and pathogens faced by
for example the poultry or cattle vaccine industry.
Nonetheless, ﬁsh oral vaccine development can greatly proﬁt
from the progress made on human and veterinary oral vaccines. For
example, the use of live vectors, e.g adenoviruses, or amore rational
attenuation of enteric pathogens, e.g E. tarda or V. anguillarum, as
well as the combination of weak oral antigens with strong mucosal
adjuvants, e.g enterotoxins, leaves a vast number of combinations
that have not been fully exploited in ﬁsh vaccine development. Fish
mucosal immunology, despite the large body of work performed in
the last 30 years, is still in its infancy, mostly due to the great
heterogeneity in teleost species. Nevertheless, the discovery of new
players in ﬁsh mucosal immunity within the last 5e10 years,
including IgT or M-like sampling cells, keeps the ﬁeld of mucosal
immunology and vaccinology a dynamic and developing area. The
possibility to speciﬁcally target M-like cells or putative APCs in the
ﬁsh gut is becoming a viable option in ﬁsh vaccine delivery as well.
This is being realized through the great advances in gene discovery
and the several genome sequencing initiatives for several ﬁsh
species and their pathogens. The bottleneck will of course be the
functional characterization of most of the novel genes and the
translation of this fundamental knowledge into practical applica-
tions linked to vaccine development. Molecular traceable and
genetically modiﬁable models such as transgenic or mutant
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much as other animal models have helped the human and veteri-
nary ﬁeld. Information on host mucosal responses, together with
insights in how ﬁsh gut microbiota might inﬂuence the response to
oral vaccination is increasing at a rapid paste. This information will
be essential to design strategies aimed at breaking mucosal toler-
ance while preventing inﬂammation for a greater variety of ﬁsh
species. Finally, collaborations between academia, industrial part-
ners and farmers will be instrumental to produce safe and efﬁca-
cious vaccines for most commercially relevant ﬁsh species.
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